JPS6149320B2 - - Google Patents
Info
- Publication number
- JPS6149320B2 JPS6149320B2 JP53019568A JP1956878A JPS6149320B2 JP S6149320 B2 JPS6149320 B2 JP S6149320B2 JP 53019568 A JP53019568 A JP 53019568A JP 1956878 A JP1956878 A JP 1956878A JP S6149320 B2 JPS6149320 B2 JP S6149320B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- polypeptides
- acid
- thymus
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 95
- 102000004196 processed proteins & peptides Human genes 0.000 description 82
- 229920001184 polypeptide Polymers 0.000 description 78
- 229940024606 amino acid Drugs 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 28
- 210000001541 thymus gland Anatomy 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- 210000003719 b-lymphocyte Anatomy 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 239000011347 resin Substances 0.000 description 18
- 229920005989 resin Polymers 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 16
- 230000004069 differentiation Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000002243 precursor Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 101150052863 THY1 gene Proteins 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- 102000044159 Ubiquitin Human genes 0.000 description 6
- 108090000848 Ubiquitin Proteins 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000000115 thoracic cavity Anatomy 0.000 description 5
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 102000006834 complement receptors Human genes 0.000 description 4
- 108010047295 complement receptors Proteins 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- -1 hydrobromic acid Chemical compound 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansÀure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 description 2
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 description 2
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000898 Thymopoietin Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000002877 alkyl aryl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 208000018360 neuromuscular disease Diseases 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- FGXOAGWXLCNHIQ-VIFPVBQESA-N (2s)-2,4-diamino-2-[(2-methylpropan-2-yl)oxycarbonyl]-4-oxobutanoic acid Chemical compound CC(C)(C)OC(=O)[C@@](N)(C(O)=O)CC(N)=O FGXOAGWXLCNHIQ-VIFPVBQESA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical group CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- GZAJOEGTZDUSKS-UHFFFAOYSA-N 5-aminofluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(N)=CC=C21 GZAJOEGTZDUSKS-UHFFFAOYSA-N 0.000 description 1
- 208000008190 Agammaglobulinemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex⢠Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000984 branchial region Anatomy 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000001538 myasthenic effect Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 239000000724 thymus hormone Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57581—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
æ¬çºæã¯æ°èŠãªããªããããé¡ïŒæ°èŠãªããªã
ãããé¡ã®è£œé æ¹æ³ïŒåã³åèšããªããããé¡ã®
çšéã«é¢ããã å€ãã®ããªããããé¡ãåç©ã®åçš®åšå®ããå
é¢ãããŠããããšã¯ããç¥ãããŠãããããããª
ãããçŽ10幎åè¿ã¯çãã人éã®äœéã®çŽ0.8ïŒ
ãå ããåšå®ã§ããèžç·ã«ã€ããŠã¯æ®ãã©ç¥ããš
ããããªããå ãã«ç¥çµçé®æç©è³ªãèžç·ã«ååš
ããŠãããšãã仮説ãæåºãããŠããã«ãããª
ããèžç·ã®æ©èœã«é¢ãã匷ãé¢å¿ãšåæã®æšè«å
ã³å®éšã«ãæãããæè¿ãŸã§èžç·ã®æ©èœã«é¢ããŠ
ã¯æ®ãã©åã€ãŠããªãã€ããããããªãããçŸåš
ã¯èžç·ã¯äžç®ïŒå åæ³ïŒæåãšãªã³ãïŒå ç«åŠ
çïŒæåãšãæããè€åšå®ã§ããåŸã€ãŠèžç·ã¯èº«
äœã®å ç«æ©èœã«é¢äžããŠããããšãåã€ããå³
ã¡ãèžç·ã¯ç¬¬ïŒé°åŒã«ç±æ¥ããäžç®ã¹ãããåã³
é è¡çµç¹ã®å¹¹çŽ°èã«ç±æ¥ãããªã³ãçãããªãè€
åšã§ããããšã¯å ¬ç¥ã§ããïŒGoldsteinçã®
ãThe Human ThymusãïŒHeinemannïŒ
LondonïŒ1969幎åç §ïŒããªã³ãçã¯èžç·å éšã§å
åãããŠïŒŽçŽ°èãšèšãããæçããèžç·ç±æ¥çŽ°è
ãšããŠèžç·ããé¢ããè¡æ¶²ïŒãªã³ãïŒèŸèïŒãªã³
ãç¯ãžãšåŸªç°ãããèžç·å éšã§ã®å¹¹çŽ°èååã®èª
å°ã¯èžç·ã®äžç®çŽ°èã®åæ³ç©ãåªä»ãšããŠèµ·ãã
ãã«æãããããçç©è©Šéšã«äŒŽãçš®ã ã®å°é£ã«ã
ãååšãããšèãããããã«ã¢ã³é¡ã®å®å šãªåé¢
åã³æ§é ã®ç¹å®ãã§ããªãã€ããšããã®ããããŸ
ã§ã®å®æ ã§ãã€ãã èžç·ã¯èº«äœã®å ç«ç¹æ§ã«é¢é£ãããããšãåã€
ãŠããã®ã§èžç·ããåé¢ãããç©è³ªã«å€å€§ã®é¢å¿
ãåããããŠãããè¿å¹Žãçã®èžç·ã«ååšããç©
質ã«é¢ããç§åŠçç 究ã«åºã¥ãæ¯èŒç倧éšã®è«æ
éãçºè¡šãããŠãããçŸã«æ¬åºé¡äººãäžèšåéã®
ç 究ã«é¢ããå€æ°ã®è«æãçºè¡šããŠãããé¢é£ã
ãåè¡ç©ãšããŠã¯ãäŸãã°ããThe LancetãïŒ
1968幎ïŒæ20æ¥å·ïŒp.119â122ïŒãTriangleãïŒ
Vol.11ïŒNo.ïŒïŒp.7â14ïŒ1972ïŒãAnnals of the
New York Academy ImmunologyãïŒVol.4ïŒNo.
ïŒïŒp.181â189ïŒ1969ïŒãNatureãïŒVol.247ïŒ
p.11â14ïŒ1974ïŒãProceedings of the National
Academy of Science USAãïŒVol.71ïŒp.1474â
1478ïŒ1974ïŒãCellãïŒVol.5ïŒP.361â365åã³367
â370ïŒ1975ïŒãLancetãïŒVol.2ïŒp.256â259ïŒ
1975ïŒãProceedings ofthe National Academy
of Sciences USAãïŒVol.72ïŒp.11â15ïŒ1975ïŒ
ãBiochemistryãVol.14ïŒp.2214â2218ïŒ1974ïŒ
ãNatureãïŒvol.255ïŒp.423â424ïŒ1975ïŒãã
ãã Goldsteinåã³Manganaroã«ãããAnnals of
the New York Academy of SciencesãïŒ
Vol.183ïŒp.230â240ïŒ1971ã®è«æã«ã¯ãåç©ã®
çç¡åçç¥çµçé害ãåŒèµ·ãèžç·ããªããããã®
ååšãé瀺ãããŠããããã®ç¥çµçé害ã¯äººéã®
ç æ°ã§ããéçæ§çç¡åçã«äŒŒããã®ã§ãããæŽ
ã«äžèšè«æã«ã¯ãçã®èžç·ã«å«ãŸããäžèšã«ç€ºã
ããšå¥ã®ããªããããé¡ã«ããïŒã€ã®å¹æãçã
ãããšã瀺ãããŠããããããã®ããªããããé¡
ã®ïŒã€ã¯ãã¢ããã·ã³ïŒThymotoxinïŒãšåä»ã
ãããŠãããã®ã§ãããã¯ççãåŒèµ·ããšæãã
ãŠããããã®ããªããããã¯åé¢ãããŠããªã
ããååéçŽ7000ã§ãããšæããã匷éœé»è·ãæ
ããã€PH8.0ã§CMâã»ãã¢ããã¯ã¹ïŒCMâ
SephadexïŒã«ä¿æãããããšãåèšè«æã«ç€ºã
ããŠããã ãNatureãïŒ247ïŒ11ïŒ1975幎ïŒæïŒæ¥å·ã«
ã¯ãããã³ïŒThymin ïŒåã³ããã³
ïŒThymin ïŒãšåºå®ãããç©è³ªãèšèŒãããŠ
ããããããã®ç©è³ªã¯çã®èžç·ããåé¢ãããæ°
ããªããããé¡ã§ãããçš®ã ã®æ²»çåéã«ç¹å®ã®
çšéãæããããšãèŠåºããããéå»ãçã®èžç·
ããåé¢ãããä»ã®ç©è³ªã«å¯ŸããŠãåæ§ã®å称ã
çšããããŠããã®ã§ãããã³ããã³ç©è³ªã¯çŸ
åšãã¢ãã€ãšãã³ïŒThymopoietin ïŒåã³
ãã¢ãã€ãšãã³ïŒThmaopoietin ïŒãšãã
ããåŒç§°ãããŠããããããã®ç©è³ªåã³ãã®è£œé
æ³ã¯1975幎ïŒæ22æ¥ä»ã§ç±³åœã«åºé¡ãããç±³åœç¹
èš±åºé¡606843å·æ现æžã«èšèŒãããŠããã ç±³åœç¹èš±ç¬¬4002602å·æ现æžã«ã¯ãéåšæ§é å
ç«æ§ããªããããïŒUbiquitous Immunopoietic
PolypeptideïŒãšããŠèšèŒãããŠããé·éããªã
ãããé¡ãé瀺ãããŠããããã®ããªããããã¯
åŸã«ãŠãããã³ïŒUbiquitinïŒãšåä»ãããã
ãã74âã¢ããé žããªããããã§ããè©Šéšç®¡äžã
ãã°ã©ã åäœã®æ¿åºŠã§éªšé«åã¯èŸèã«ååšããå
é§ç©è³ªãã现èåã³ïŒ¢çŽ°èã®ååãèªå°ããèœ
åãç¹åŸŽãšãããã®ã§ãããåŸã€ãŠãäžèšããªã
ãããã¯èžç·åã¯å ç«æ¬ é¥åã¯æ¬ 倱çã®æ²»çåé
ã«æå¹ã§ããã 1977幎ïŒæ11æ¥ä»ã§çºè¡ãããç±³åœç¹èš±ç¬¬
4002740å·æ现æžã«ã¯ãåæããªãã«ããããçµ
æç©ãé瀺ãããŠããããããã®ããªãã«ããã
ãçµæç©ã¯è£äœå容äœã§ããâãªã³ãçã§ã¯ãª
ãâãªã³ãçã®ååãèªå°ããããšãã§ããã
åŸã€ãŠããã®ããªããããã¯äžè¿°ç±³åœç¹èš±åºé¡ç¬¬
606843å·æ现æžã«æŒããŠãã¢ãã€ãšãã³ãšããŠå
é¢ãããé·éããªããããé¡ã®ç¹æ§ã®å å€ãã®ã
ã®ããã®ç¹æ§ãšããŠç€ºããã æ¬çºæã¯äžå®ã®æŽ»æ§éšæ§é åäœãæããåæïŒ
âã¢ããé žããªãããããæäŸãããã®ã§ããã
ãã®ããªããããã¯äžè¿°åè¡ç©åã³ç±³åœç¹èš±ç¬¬
4002602å·æ现æžã«æŒããŠéåšæ§é å ç«æ§ããªã
ãããïŒUBIPïŒãšããŠåé¢ãããé·éããªãã
ããã®æã€å€ãã®ç¹æ§ããã®ç¹æ§ãšããŠç€ºãããš
ãåã€ãã åŸã€ãŠãæ¬çºæã®ç®çã¯çç©åŠçã«éèŠã§ãã
æ°èŠãªããªããããé¡ãæäŸããããšã§ããã æ¬çºæã®ä»ã®ç®çã¯ããã°ã©ã åäœã®æ¿åºŠã§ïŒ¢
âå é§äœçŽ°èãšïŒŽâå é§äœçŽ°èãšãååã§ããåŸ
ã€ãŠäººéåã³åç©ã®å ç«ç³»ã«éåžžã«æå¹ã§ããæ°
èŠãªããªããããé¡ãæäŸããããšã§ããã æ¬çºæã®æŽã«ä»ã®ç®çã¯çååŠäœçšã«äœ¿çšãã
çµæç©åã³æ¹æ³ãšåæã«æ°èŠãªäžéäœçæç©ãšæ°
èŠãªããªããããé¡ãåæããæ¹æ³ãšãæäŸãã
ããšã§ããã 以äžãæ¬çºæãæŽã«è©³ãã説æããã æ¬çºæã®æ°èŠãªããªããããé¡ã¯æŽ»æ§éšäœåã¯
æåãšããŠäžèšæ§é åäœãæãããã®ã§ããã ââââGLNâLYSâ äžåŒã«æŒããŠãã¯TYRåã¯ALAïŒïŒ¹ã¯ASN
åã¯ALAïŒïŒºã¯ILEåã¯ALAãè¡šããã æŽã«ãæ¬çºæã¯åèšããªããããã®è£œé éçšã§
圢æãããæ°èŠãªããªããããâæš¹èäžéäœãæ
äŸãããã®ã§ããããã®äžéäœã¯äžèšåŒã§è¡šãã
ããã äžåŒã«ãããŠãïŒïŒ¹åã³ïŒºã¯åè¿°ã®éãã§ã
ããR1ïŒR2åã³R3ã¯ãå¿ èŠã«ããããããã瀺
ãããŠããåã¢ããé žã«çµåããŠããä¿è·åºã§ã
ããæš¹èã¯åå¿æ¯æäœãšããŠäœçšããåºçžé«åå
ç©è³ªã§ããããªããäžåŒã«æŒããŠæš¹èåã³ä¿è·åº
ã®ãªãããããäžéäœãæ¬çºæã®æäŸãããã®ã§
ãããæ¬çºæã¯æŽã«åºçžããããåææ³ã«ããã
ãªããããã®è£œé æ¹æ³ïŒåèšããªãããããå«ã
æ²»ççµæç©ïŒåã³äººéåã³åç©ã«ããªããããã
æäžããŠçååŠçã«äœçšãããæ¹æ³ããæäŸã
ãã äžè¿°ã®åŠããæ¬çºæã¯çš®ã ã®åéã«æ²»çå¹æã
æããæ°èŠãªããªããããé¡ïŒããªããããé¡ã®
補é éçšã§çããçš®ã ã®äžéäœïŒæ²»ççšçµæç©ïŒ
åèšããªããããé¡ãå©çšããçšè¿°ïŒåã³ããªã
ãããé¡ã®è£œé æ¹æ³ã«é¢ãããã®ã§ããã æ¬çºæã®äž»ããå®æœæ æ§ã«ããã°ã掻æ§éšäœãš
ããŠäžèšã¢ããé žæ§é åäœãæããããªãããã
é¡ãæäŸãããŠããã ïŒïŒžâââGLNâLYS äžåŒã«æŒããŠãã¯TYRåã¯ALAïŒïŒ¹ã¯ASN
åã¯ALAïŒåã³ïŒºã¯ILEåã¯ALAã§ãããïŒç¹
ã«å¥œãŸããã®ã¯ïŒžãTYRïŒïŒ¹ãASNïŒïŒºãILE
ã®å Žåã§ããã æŽã«ã掻æ§éšäœãšããŠäžèšæ§é äœãå«ããã®ã§
ãã€ãŠäžèšäžè¬åŒã§è¡šãããããã³ã¿ããªããã
ããæäŸãããŠããã ã»ïŒ²âNHââââGLNâLYSâ
CORâ² äžåŒã§ãïŒïŒ¹åã³ïŒºã¯äžè¿°ã®éãã§ããã
åã³Râ²ã¯ãããããã³ã¿ããããæ§é äœã«çµå
ããŠãã眮æäœã§ããããããã®çœ®æäœã¯ã¢ãã
é žã®åºäœåœ¢æŽ»æ§æ§é äœã®çååŠç掻æ§ã«å®è³ªäžåœ±
é¿ãäžããªããã®ã§ãããåŒïŒïŒã®æå³ãããš
ããã¯ããããã®ïŒã€ã®æ«ç«¯ã¢ããé žã«ãã³ã¿ã
ãããååã®çååŠç掻æ§ã«å®è³ªçãªåœ±é¿ãåãŒ
ããªãå®èœåºåã¯èªå°äœïŒå³ã¡ãåã³Râ²ïŒã
çµåãããããšã«ããæ¬çºæã®ç¯å²ãéžè±ããã
ãšãªããã®ãã³ã¿ããããéã®æ«ç«¯ã¢ããé žãæ¹
質ããããšãã§ãããšããããšã§ãããåŸã€ãŠã
æ«ç«¯ã¢ããé žåºåã³ã«ã«ãã³é žåºã¯æãçš®ã®ããª
ããããé¡ã®å Žåãšåæ§ã«ãã³ã¿ããããã®çå
åŠç掻æ§ä»äžã«é¢ããŠå¿ é ã®ãã®ã§ãªããšããã
ãšã§ãããããæ ãæ¬çºæã¯æ«ç«¯ã¢ããé žãæªçœ®
æã®ãã³ã¿ããããé¡åã³æ¬çºæã«èšãçååŠç
掻æ§ã«å®è³ªçã«åœ±é¿ãåãŒããªãïŒçš®åã¯ãã以
äžã®å®èœåºã«ããæ«ç«¯åºã眮æãããŠãããã³ã¿
ããããé¡ã®äž¡è ããã®ç¯å²ã«å«ããã®ã§ããã ãããã®å®èœåºã®çœ®æãšããŠã¯éé¢ã¢ããåºã®
ã¢ã·ã«ååã³éé¢ã«ã«ãã³é žåºã®ã¢ããåã®ãã
ãªéåžžã®çœ®æïŒåã³ä»ã®ã¢ããé žé¡ã®çœ®æãå«ãŸ
ããããããã®èŠ³ç¹ããèŠãæãæ¬çºæã®ãã³ã¿
ããããé¡ã¯ç¹ç°ãªãã®ã§ãããšæããããäœæ
ãªããæ¬çºæã®ãã³ã¿ããããé¡ã¯åèšãããã
æ§é åäœããã®äžéšãšããŠå«ãé·é倩ç¶ãããã
é¡ãšåãçååŠæŽ»æ§ã瀺ãããã§ãããããæ ã
ããããååã®çååŠç掻æ§ã¯ååã®ç«äœååŠç
ç¹åŸŽãå³ã¡ååã®ç¹å®ãªæãããã¿æ§é ã«èµ·å ã
ãŠãããšæããããããªããããã®çµåã¯åçŽã§
ãªãæè»ã§ãããã€ã·ãŒãç¶ïŒãããç¶çã®åœ¢ç¶
ã§ååšããŠããããã®çµæãååå šäœãšããŠã¯æ
è»ãšãªãäžå®ã®ç¶æ ã§æãéãªã€ãŠãããæ¬çºæ
è ã¯æ¬çºæã®ãã³ã¿ããããã¯é·éã®å€©ç¶ããªã
ããããšåæ§ãªæãéãªãæ§é ãæãããæ åæ§
ã®çååŠçç¹æ§ã瀺ãããšãèŠåºããããã®æ§ãª
èš³ã§ãå®è³ªäžçååŠç掻æ§ã«åœ±é¿ãäžããªã眮æ
åºã§ãããåã¯ãã³ã¿ããããååã®å€©ç¶éç³æ§
é ãé»å®³ããªã眮æåºã§ããã°ãã³ã¿ããããã
çš®ã ã®å®èœåºã§çœ®æããããšãã§ããã ãã³ã¿ããããååã®çååŠçç¹æ§åã³å€©ç¶é
ç³æ§é ãä¿æããèœåã¯æ¬¡ã®äºå®ããæããã§ã
ããå³ã¡ãæ¬çºæã®ãã³ã¿ããããæ§é äœã¯ç±³åœ
ç¹èš±ç¬¬4002602å·ã«æŒããŠãŠãããã³
ïŒUbiquitinïŒãšããŠé瀺ããã倩ç¶ã®74âã¢ãã
é žãããããšåãçååŠç¹æ§ã瀺ããšããäºå®ã§
ããããã®é·éã®ããªããããã®ååã®å éšã«æŒ
ããŠäžèšç¹èš±ã«èšèŒãããŠããä»ã®ã¢ããé žãšçµ
åããŠãããšãã圢ã§ã¯ãããæ¬çºæã®ãã³ã¿ã
ããããåå®ããããšãã§ãããããããªããã
æ¬çºæã®ãã³ã¿ãããããšãŠãããã³ãšã®çååŠ
掻æ§ã¯åäžã§ãããã€æ«ç«¯ã¢ããé žã眮æãããŠ
ããã¢ããé žé¡åã³ããããéã¯åºæ¬åœ¢ãã³ã¿ã
ãããæ§é äœã®çååŠç¹æ§ã«åœ±é¿ãåãŒããªãæ
ã«æ¬çºæã®ãã³ã¿ããããã掻æ§éšäœã§ãããšã
ãããšãäžèšç¹èš±ã¯çŽæ¥ç«èšŒããŠããã®ã§ããã ãã®ããšãããåŒïŒïŒã®ïŒ²åã³Râ²ãšããŠã¯
åºæ¬åœ¢æŽ»æ§æ§é äœã®çååŠç掻æ§ã«å®è³ªäžåœ±é¿ã
äžããªãããããããªã眮æäœã§ã䜿çšã§ããã
ãšãç解ãããã§ããããåã³Râ²ã¯äŸãã°äž
èšçœ®æåºã®ãããã§ãããã  Râ² æ°Ž çŽ OH C1âC7ã¢ã«ãã« NH2 C5âC12ã¢ãªãŒã« NHR7 C6âC20ã¢ã«ã«ãªãŒã« ïŒR7ïŒ2 C6âC20ã¢ã«ã¢ã«ãã« OR7 C1âC7ã¢ã«ã«ãã€ã« C2âC7ã¢ã«ã±ãã« C2âC7ã¢ã«ããã« ããã§ãR7ã¯C1âC7ã®ã¢ã«ãã«ïŒC2âC7ã®ã¢
ã«ã±ãã«ïŒC2âC7ã®ã¢ã«ããã«ïŒC6âC20ã®ã¢ãª
ãŒã«ïŒC6âC20ã®ã¢ã«ã«ãªãŒã«åã¯C6âC20ã®ã¢
ã«ã¢ã«ãã«ã瀺ãã åã³Râ²ã¯åäžæ§ã¢ããé žåºåã¯ççŽ ååæ°
ïŒâ20ã®ããªããããéã®æ®åºã§ãã€ãŠãããã
ãããã®äŸãäžèšã«ç€ºãã
ãããé¡ã®è£œé æ¹æ³ïŒåã³åèšããªããããé¡ã®
çšéã«é¢ããã å€ãã®ããªããããé¡ãåç©ã®åçš®åšå®ããå
é¢ãããŠããããšã¯ããç¥ãããŠãããããããª
ãããçŽ10幎åè¿ã¯çãã人éã®äœéã®çŽ0.8ïŒ
ãå ããåšå®ã§ããèžç·ã«ã€ããŠã¯æ®ãã©ç¥ããš
ããããªããå ãã«ç¥çµçé®æç©è³ªãèžç·ã«ååš
ããŠãããšãã仮説ãæåºãããŠããã«ãããª
ããèžç·ã®æ©èœã«é¢ãã匷ãé¢å¿ãšåæã®æšè«å
ã³å®éšã«ãæãããæè¿ãŸã§èžç·ã®æ©èœã«é¢ããŠ
ã¯æ®ãã©åã€ãŠããªãã€ããããããªãããçŸåš
ã¯èžç·ã¯äžç®ïŒå åæ³ïŒæåãšãªã³ãïŒå ç«åŠ
çïŒæåãšãæããè€åšå®ã§ããåŸã€ãŠèžç·ã¯èº«
äœã®å ç«æ©èœã«é¢äžããŠããããšãåã€ããå³
ã¡ãèžç·ã¯ç¬¬ïŒé°åŒã«ç±æ¥ããäžç®ã¹ãããåã³
é è¡çµç¹ã®å¹¹çŽ°èã«ç±æ¥ãããªã³ãçãããªãè€
åšã§ããããšã¯å ¬ç¥ã§ããïŒGoldsteinçã®
ãThe Human ThymusãïŒHeinemannïŒ
LondonïŒ1969幎åç §ïŒããªã³ãçã¯èžç·å éšã§å
åãããŠïŒŽçŽ°èãšèšãããæçããèžç·ç±æ¥çŽ°è
ãšããŠèžç·ããé¢ããè¡æ¶²ïŒãªã³ãïŒèŸèïŒãªã³
ãç¯ãžãšåŸªç°ãããèžç·å éšã§ã®å¹¹çŽ°èååã®èª
å°ã¯èžç·ã®äžç®çŽ°èã®åæ³ç©ãåªä»ãšããŠèµ·ãã
ãã«æãããããçç©è©Šéšã«äŒŽãçš®ã ã®å°é£ã«ã
ãååšãããšèãããããã«ã¢ã³é¡ã®å®å šãªåé¢
åã³æ§é ã®ç¹å®ãã§ããªãã€ããšããã®ããããŸ
ã§ã®å®æ ã§ãã€ãã èžç·ã¯èº«äœã®å ç«ç¹æ§ã«é¢é£ãããããšãåã€
ãŠããã®ã§èžç·ããåé¢ãããç©è³ªã«å€å€§ã®é¢å¿
ãåããããŠãããè¿å¹Žãçã®èžç·ã«ååšããç©
質ã«é¢ããç§åŠçç 究ã«åºã¥ãæ¯èŒç倧éšã®è«æ
éãçºè¡šãããŠãããçŸã«æ¬åºé¡äººãäžèšåéã®
ç 究ã«é¢ããå€æ°ã®è«æãçºè¡šããŠãããé¢é£ã
ãåè¡ç©ãšããŠã¯ãäŸãã°ããThe LancetãïŒ
1968幎ïŒæ20æ¥å·ïŒp.119â122ïŒãTriangleãïŒ
Vol.11ïŒNo.ïŒïŒp.7â14ïŒ1972ïŒãAnnals of the
New York Academy ImmunologyãïŒVol.4ïŒNo.
ïŒïŒp.181â189ïŒ1969ïŒãNatureãïŒVol.247ïŒ
p.11â14ïŒ1974ïŒãProceedings of the National
Academy of Science USAãïŒVol.71ïŒp.1474â
1478ïŒ1974ïŒãCellãïŒVol.5ïŒP.361â365åã³367
â370ïŒ1975ïŒãLancetãïŒVol.2ïŒp.256â259ïŒ
1975ïŒãProceedings ofthe National Academy
of Sciences USAãïŒVol.72ïŒp.11â15ïŒ1975ïŒ
ãBiochemistryãVol.14ïŒp.2214â2218ïŒ1974ïŒ
ãNatureãïŒvol.255ïŒp.423â424ïŒ1975ïŒãã
ãã Goldsteinåã³Manganaroã«ãããAnnals of
the New York Academy of SciencesãïŒ
Vol.183ïŒp.230â240ïŒ1971ã®è«æã«ã¯ãåç©ã®
çç¡åçç¥çµçé害ãåŒèµ·ãèžç·ããªããããã®
ååšãé瀺ãããŠããããã®ç¥çµçé害ã¯äººéã®
ç æ°ã§ããéçæ§çç¡åçã«äŒŒããã®ã§ãããæŽ
ã«äžèšè«æã«ã¯ãçã®èžç·ã«å«ãŸããäžèšã«ç€ºã
ããšå¥ã®ããªããããé¡ã«ããïŒã€ã®å¹æãçã
ãããšã瀺ãããŠããããããã®ããªããããé¡
ã®ïŒã€ã¯ãã¢ããã·ã³ïŒThymotoxinïŒãšåä»ã
ãããŠãããã®ã§ãããã¯ççãåŒèµ·ããšæãã
ãŠããããã®ããªããããã¯åé¢ãããŠããªã
ããååéçŽ7000ã§ãããšæããã匷éœé»è·ãæ
ããã€PH8.0ã§CMâã»ãã¢ããã¯ã¹ïŒCMâ
SephadexïŒã«ä¿æãããããšãåèšè«æã«ç€ºã
ããŠããã ãNatureãïŒ247ïŒ11ïŒ1975幎ïŒæïŒæ¥å·ã«
ã¯ãããã³ïŒThymin ïŒåã³ããã³
ïŒThymin ïŒãšåºå®ãããç©è³ªãèšèŒãããŠ
ããããããã®ç©è³ªã¯çã®èžç·ããåé¢ãããæ°
ããªããããé¡ã§ãããçš®ã ã®æ²»çåéã«ç¹å®ã®
çšéãæããããšãèŠåºããããéå»ãçã®èžç·
ããåé¢ãããä»ã®ç©è³ªã«å¯ŸããŠãåæ§ã®å称ã
çšããããŠããã®ã§ãããã³ããã³ç©è³ªã¯çŸ
åšãã¢ãã€ãšãã³ïŒThymopoietin ïŒåã³
ãã¢ãã€ãšãã³ïŒThmaopoietin ïŒãšãã
ããåŒç§°ãããŠããããããã®ç©è³ªåã³ãã®è£œé
æ³ã¯1975幎ïŒæ22æ¥ä»ã§ç±³åœã«åºé¡ãããç±³åœç¹
èš±åºé¡606843å·æ现æžã«èšèŒãããŠããã ç±³åœç¹èš±ç¬¬4002602å·æ现æžã«ã¯ãéåšæ§é å
ç«æ§ããªããããïŒUbiquitous Immunopoietic
PolypeptideïŒãšããŠèšèŒãããŠããé·éããªã
ãããé¡ãé瀺ãããŠããããã®ããªããããã¯
åŸã«ãŠãããã³ïŒUbiquitinïŒãšåä»ãããã
ãã74âã¢ããé žããªããããã§ããè©Šéšç®¡äžã
ãã°ã©ã åäœã®æ¿åºŠã§éªšé«åã¯èŸèã«ååšããå
é§ç©è³ªãã现èåã³ïŒ¢çŽ°èã®ååãèªå°ããèœ
åãç¹åŸŽãšãããã®ã§ãããåŸã€ãŠãäžèšããªã
ãããã¯èžç·åã¯å ç«æ¬ é¥åã¯æ¬ 倱çã®æ²»çåé
ã«æå¹ã§ããã 1977幎ïŒæ11æ¥ä»ã§çºè¡ãããç±³åœç¹èš±ç¬¬
4002740å·æ现æžã«ã¯ãåæããªãã«ããããçµ
æç©ãé瀺ãããŠããããããã®ããªãã«ããã
ãçµæç©ã¯è£äœå容äœã§ããâãªã³ãçã§ã¯ãª
ãâãªã³ãçã®ååãèªå°ããããšãã§ããã
åŸã€ãŠããã®ããªããããã¯äžè¿°ç±³åœç¹èš±åºé¡ç¬¬
606843å·æ现æžã«æŒããŠãã¢ãã€ãšãã³ãšããŠå
é¢ãããé·éããªããããé¡ã®ç¹æ§ã®å å€ãã®ã
ã®ããã®ç¹æ§ãšããŠç€ºããã æ¬çºæã¯äžå®ã®æŽ»æ§éšæ§é åäœãæããåæïŒ
âã¢ããé žããªãããããæäŸãããã®ã§ããã
ãã®ããªããããã¯äžè¿°åè¡ç©åã³ç±³åœç¹èš±ç¬¬
4002602å·æ现æžã«æŒããŠéåšæ§é å ç«æ§ããªã
ãããïŒUBIPïŒãšããŠåé¢ãããé·éããªãã
ããã®æã€å€ãã®ç¹æ§ããã®ç¹æ§ãšããŠç€ºãããš
ãåã€ãã åŸã€ãŠãæ¬çºæã®ç®çã¯çç©åŠçã«éèŠã§ãã
æ°èŠãªããªããããé¡ãæäŸããããšã§ããã æ¬çºæã®ä»ã®ç®çã¯ããã°ã©ã åäœã®æ¿åºŠã§ïŒ¢
âå é§äœçŽ°èãšïŒŽâå é§äœçŽ°èãšãååã§ããåŸ
ã€ãŠäººéåã³åç©ã®å ç«ç³»ã«éåžžã«æå¹ã§ããæ°
èŠãªããªããããé¡ãæäŸããããšã§ããã æ¬çºæã®æŽã«ä»ã®ç®çã¯çååŠäœçšã«äœ¿çšãã
çµæç©åã³æ¹æ³ãšåæã«æ°èŠãªäžéäœçæç©ãšæ°
èŠãªããªããããé¡ãåæããæ¹æ³ãšãæäŸãã
ããšã§ããã 以äžãæ¬çºæãæŽã«è©³ãã説æããã æ¬çºæã®æ°èŠãªããªããããé¡ã¯æŽ»æ§éšäœåã¯
æåãšããŠäžèšæ§é åäœãæãããã®ã§ããã ââââGLNâLYSâ äžåŒã«æŒããŠãã¯TYRåã¯ALAïŒïŒ¹ã¯ASN
åã¯ALAïŒïŒºã¯ILEåã¯ALAãè¡šããã æŽã«ãæ¬çºæã¯åèšããªããããã®è£œé éçšã§
圢æãããæ°èŠãªããªããããâæš¹èäžéäœãæ
äŸãããã®ã§ããããã®äžéäœã¯äžèšåŒã§è¡šãã
ããã äžåŒã«ãããŠãïŒïŒ¹åã³ïŒºã¯åè¿°ã®éãã§ã
ããR1ïŒR2åã³R3ã¯ãå¿ èŠã«ããããããã瀺
ãããŠããåã¢ããé žã«çµåããŠããä¿è·åºã§ã
ããæš¹èã¯åå¿æ¯æäœãšããŠäœçšããåºçžé«åå
ç©è³ªã§ããããªããäžåŒã«æŒããŠæš¹èåã³ä¿è·åº
ã®ãªãããããäžéäœãæ¬çºæã®æäŸãããã®ã§
ãããæ¬çºæã¯æŽã«åºçžããããåææ³ã«ããã
ãªããããã®è£œé æ¹æ³ïŒåèšããªãããããå«ã
æ²»ççµæç©ïŒåã³äººéåã³åç©ã«ããªããããã
æäžããŠçååŠçã«äœçšãããæ¹æ³ããæäŸã
ãã äžè¿°ã®åŠããæ¬çºæã¯çš®ã ã®åéã«æ²»çå¹æã
æããæ°èŠãªããªããããé¡ïŒããªããããé¡ã®
補é éçšã§çããçš®ã ã®äžéäœïŒæ²»ççšçµæç©ïŒ
åèšããªããããé¡ãå©çšããçšè¿°ïŒåã³ããªã
ãããé¡ã®è£œé æ¹æ³ã«é¢ãããã®ã§ããã æ¬çºæã®äž»ããå®æœæ æ§ã«ããã°ã掻æ§éšäœãš
ããŠäžèšã¢ããé žæ§é åäœãæããããªãããã
é¡ãæäŸãããŠããã ïŒïŒžâââGLNâLYS äžåŒã«æŒããŠãã¯TYRåã¯ALAïŒïŒ¹ã¯ASN
åã¯ALAïŒåã³ïŒºã¯ILEåã¯ALAã§ãããïŒç¹
ã«å¥œãŸããã®ã¯ïŒžãTYRïŒïŒ¹ãASNïŒïŒºãILE
ã®å Žåã§ããã æŽã«ã掻æ§éšäœãšããŠäžèšæ§é äœãå«ããã®ã§
ãã€ãŠäžèšäžè¬åŒã§è¡šãããããã³ã¿ããªããã
ããæäŸãããŠããã ã»ïŒ²âNHââââGLNâLYSâ
CORâ² äžåŒã§ãïŒïŒ¹åã³ïŒºã¯äžè¿°ã®éãã§ããã
åã³Râ²ã¯ãããããã³ã¿ããããæ§é äœã«çµå
ããŠãã眮æäœã§ããããããã®çœ®æäœã¯ã¢ãã
é žã®åºäœåœ¢æŽ»æ§æ§é äœã®çååŠç掻æ§ã«å®è³ªäžåœ±
é¿ãäžããªããã®ã§ãããåŒïŒïŒã®æå³ãããš
ããã¯ããããã®ïŒã€ã®æ«ç«¯ã¢ããé žã«ãã³ã¿ã
ãããååã®çååŠç掻æ§ã«å®è³ªçãªåœ±é¿ãåãŒ
ããªãå®èœåºåã¯èªå°äœïŒå³ã¡ãåã³Râ²ïŒã
çµåãããããšã«ããæ¬çºæã®ç¯å²ãéžè±ããã
ãšãªããã®ãã³ã¿ããããéã®æ«ç«¯ã¢ããé žãæ¹
質ããããšãã§ãããšããããšã§ãããåŸã€ãŠã
æ«ç«¯ã¢ããé žåºåã³ã«ã«ãã³é žåºã¯æãçš®ã®ããª
ããããé¡ã®å Žåãšåæ§ã«ãã³ã¿ããããã®çå
åŠç掻æ§ä»äžã«é¢ããŠå¿ é ã®ãã®ã§ãªããšããã
ãšã§ãããããæ ãæ¬çºæã¯æ«ç«¯ã¢ããé žãæªçœ®
æã®ãã³ã¿ããããé¡åã³æ¬çºæã«èšãçååŠç
掻æ§ã«å®è³ªçã«åœ±é¿ãåãŒããªãïŒçš®åã¯ãã以
äžã®å®èœåºã«ããæ«ç«¯åºã眮æãããŠãããã³ã¿
ããããé¡ã®äž¡è ããã®ç¯å²ã«å«ããã®ã§ããã ãããã®å®èœåºã®çœ®æãšããŠã¯éé¢ã¢ããåºã®
ã¢ã·ã«ååã³éé¢ã«ã«ãã³é žåºã®ã¢ããåã®ãã
ãªéåžžã®çœ®æïŒåã³ä»ã®ã¢ããé žé¡ã®çœ®æãå«ãŸ
ããããããã®èŠ³ç¹ããèŠãæãæ¬çºæã®ãã³ã¿
ããããé¡ã¯ç¹ç°ãªãã®ã§ãããšæããããäœæ
ãªããæ¬çºæã®ãã³ã¿ããããé¡ã¯åèšãããã
æ§é åäœããã®äžéšãšããŠå«ãé·é倩ç¶ãããã
é¡ãšåãçååŠæŽ»æ§ã瀺ãããã§ãããããæ ã
ããããååã®çååŠç掻æ§ã¯ååã®ç«äœååŠç
ç¹åŸŽãå³ã¡ååã®ç¹å®ãªæãããã¿æ§é ã«èµ·å ã
ãŠãããšæããããããªããããã®çµåã¯åçŽã§
ãªãæè»ã§ãããã€ã·ãŒãç¶ïŒãããç¶çã®åœ¢ç¶
ã§ååšããŠããããã®çµæãååå šäœãšããŠã¯æ
è»ãšãªãäžå®ã®ç¶æ ã§æãéãªã€ãŠãããæ¬çºæ
è ã¯æ¬çºæã®ãã³ã¿ããããã¯é·éã®å€©ç¶ããªã
ããããšåæ§ãªæãéãªãæ§é ãæãããæ åæ§
ã®çååŠçç¹æ§ã瀺ãããšãèŠåºããããã®æ§ãª
èš³ã§ãå®è³ªäžçååŠç掻æ§ã«åœ±é¿ãäžããªã眮æ
åºã§ãããåã¯ãã³ã¿ããããååã®å€©ç¶éç³æ§
é ãé»å®³ããªã眮æåºã§ããã°ãã³ã¿ããããã
çš®ã ã®å®èœåºã§çœ®æããããšãã§ããã ãã³ã¿ããããååã®çååŠçç¹æ§åã³å€©ç¶é
ç³æ§é ãä¿æããèœåã¯æ¬¡ã®äºå®ããæããã§ã
ããå³ã¡ãæ¬çºæã®ãã³ã¿ããããæ§é äœã¯ç±³åœ
ç¹èš±ç¬¬4002602å·ã«æŒããŠãŠãããã³
ïŒUbiquitinïŒãšããŠé瀺ããã倩ç¶ã®74âã¢ãã
é žãããããšåãçååŠç¹æ§ã瀺ããšããäºå®ã§
ããããã®é·éã®ããªããããã®ååã®å éšã«æŒ
ããŠäžèšç¹èš±ã«èšèŒãããŠããä»ã®ã¢ããé žãšçµ
åããŠãããšãã圢ã§ã¯ãããæ¬çºæã®ãã³ã¿ã
ããããåå®ããããšãã§ãããããããªããã
æ¬çºæã®ãã³ã¿ãããããšãŠãããã³ãšã®çååŠ
掻æ§ã¯åäžã§ãããã€æ«ç«¯ã¢ããé žã眮æãããŠ
ããã¢ããé žé¡åã³ããããéã¯åºæ¬åœ¢ãã³ã¿ã
ãããæ§é äœã®çååŠç¹æ§ã«åœ±é¿ãåãŒããªãæ
ã«æ¬çºæã®ãã³ã¿ããããã掻æ§éšäœã§ãããšã
ãããšãäžèšç¹èš±ã¯çŽæ¥ç«èšŒããŠããã®ã§ããã ãã®ããšãããåŒïŒïŒã®ïŒ²åã³Râ²ãšããŠã¯
åºæ¬åœ¢æŽ»æ§æ§é äœã®çååŠç掻æ§ã«å®è³ªäžåœ±é¿ã
äžããªãããããããªã眮æäœã§ã䜿çšã§ããã
ãšãç解ãããã§ããããåã³Râ²ã¯äŸãã°äž
èšçœ®æåºã®ãããã§ãããã  Râ² æ°Ž çŽ OH C1âC7ã¢ã«ãã« NH2 C5âC12ã¢ãªãŒã« NHR7 C6âC20ã¢ã«ã«ãªãŒã« ïŒR7ïŒ2 C6âC20ã¢ã«ã¢ã«ãã« OR7 C1âC7ã¢ã«ã«ãã€ã« C2âC7ã¢ã«ã±ãã« C2âC7ã¢ã«ããã« ããã§ãR7ã¯C1âC7ã®ã¢ã«ãã«ïŒC2âC7ã®ã¢
ã«ã±ãã«ïŒC2âC7ã®ã¢ã«ããã«ïŒC6âC20ã®ã¢ãª
ãŒã«ïŒC6âC20ã®ã¢ã«ã«ãªãŒã«åã¯C6âC20ã®ã¢
ã«ã¢ã«ãã«ã瀺ãã åã³Râ²ã¯åäžæ§ã¢ããé žåºåã¯ççŽ ååæ°
ïŒâ20ã®ããªããããéã®æ®åºã§ãã€ãŠãããã
ãããã®äŸãäžèšã«ç€ºãã
ãè¡šã
ãè¡šã
æ¬çºæã®æŽã«å
·äœçãªæ
æ§ã«ããã°ãæ¬çºæã¯
äžèšåŒãæããæ°èŠãªãã³ã¿ããããããæäŸã
ããã®ã§ããã ïŒïŒ²âHNâTYRâASNâILEâGLNâLYS
âCORâ² äžåŒã§ãã¯æ°ŽçŽ ïŒã¡ãã«ïŒãšãã«çã®C1â
C7ã®ã¢ã«ãã«ïŒããšãã«çã®C5âC12ã¢ãªãŒã«ïŒ
ã¢ã»ãã«ïŒããããªãã«çã®C1âC7ã®ã¢ã«ã«ã
ã€ã«ïŒRâ²ã¯OHïŒNH2ïŒNHR7ïŒïŒ®ïŒR7ïŒ2åã¯å¡©çŽ
ã瀺ããæã奜ãŸããããªããããé¡ã¯ïŒ²ãæ°Ž
çŽ ïŒRâ²ãOHã§ããããããé¡ã§ããã ãã³ã¿ããããé¡ã®è¬çåŠäžæºè¶³ãåŸããã³ã¿
ããããã®å¡©é¡ãåæ¬çºæã®ç¯å²ã«å«ãŸãããã
ã³ã¿ãããããšå¡©ã圢æãåŸãé žãšããŠã¯å¡©é žïŒ
èåæ°ŽçŽ é žïŒéé žçŽ é žïŒç¡é žïŒããªã·ã¢ã³é žïŒç¡«
é žïŒçé žçã®ç¡æ©é žãšè»é žïŒé ¢é žïŒããããªã³
é žïŒã°ãªã³ãŒã«é žïŒä¹³é žïŒãã«ãã³é žïŒèé žïŒã
ãã³é žïŒã³ãã¯é žïŒãã¬ã€ã³é žïŒãããŒã«é žïŒã¢
ã³ãã©ãã«é žïŒæ±ç®é žïŒããã¿ãªã³ã¹ã«ãã³é žïŒ
ã¹ã«ãã¢ãã«é žçã®ææ©é žãšãæããããšãã§ã
ãã äžèšæ§é äœã«æŒããŠããããã®ã¢ããé žæåã¯
䟿å®äžç¥å·ã§ç€ºãããããããã®ç¥å·ã¯äžèšã¢ã
ãé žã瀺ãã ã¢ããé ž ç¥ å· ïŒ¬âããã·ã³ TYR âã¢ã¹ãã©ã®ã³ ASN âã¢ã¹ãã©ã®ã³é ž ASP âã€ãœãã€ã·ã³ ILE âã»ãªã³ SER âã°ã«ã¿ãã³ GLN âãã€ã·ã³ LEU âãªã·ã³ LYS âã°ã«ã¿ãã³é ž GLU âã¹ã¬ãªãã³ THR âãã¹ããžã³ HIS âããªã³ VAL âã¢ã«ã®ãã³ ARG âã¢ã©ãã³ ALA æ¬çºæã®ããªããããé¡ã¯ïŒâã¢ããé žããã
ãé¡ã§ããããã®ããããã¯ç±³åœç¹èš±ç¬¬4002602
å·ã«é瀺ãããŠããåŠãçã®èžç·ããåé¢ããã
74âã¢ããé žããªããããã§ãããŠãããã³
ïŒUBIPïŒã«äŒŒãç¹æ§ã瀺ãããšãåã€ããæ¬çºæ
ã®ããããé¡ã¯ããã°ã©ã åäœã®æ¿åºŠã§ïŒ¢å é§äœ
现èãšåæã«ïŒŽå é§äœçŽ°èã®éžæçååãèªå°ã
ãããšãã§ããç¹ã«ãã®ç¹åŸŽããããæ¬çºæã®ã
ãªããããé¡ã¯ç±³åœç¹åŸŽç¬¬4002602å·ã«é瀺ãã
ãŠããé·éããªããããé¡ãšåæ§ã«è©Šéšç®¡äžã§å
ç«çŽ°èå é§äœçŽ°èãååãããããšãåã€ããå³
ã¡ãæ¬çºæã®ããªããããé¡ã¯äŸãããã°ã©ã å
äœã®æ¿åºŠã§ãèžç·ååæåTLåã³THYâïŒ
ïŒÎžïŒã®ç²åŸã«ãã枬å®ããããããªïŒŽå é§äœçŽ°
èãšïŒ¢çŽ°èã®èå¥ããŒã«ãŒïŒmarkerïŒã§ããè£
äœå容äœã®ç²åŸã«ãã枬å®ããããããªïŒ¢å é§äœ
现èãšã®ååãèªå°ããããšãåã€ãã æ¬çºæã®ããªããããé¡ã®çååŠçååç¹æ§ã®
éèŠæ§ãç解ããã«ã¯ãå ç«ã«é¢ããèžç·ã®æ©èœ
ã¯åºçŸ©ã«èšãã°ïŒŽçŽ°èãšèšãããèžç·ã«ç±æ¥ãã
现èå³ã¡ãªã³ãçãçæããããšã§ãããšããã
ãšãã§ããããšãéèšãã¹ãã§ããã现èã¯å
埪ç°å°ãªã³ãç貯槜ã®å€§éšåã圢æããŠããã
现èã¯å ç«åŠçç¹ç°æ§ãæããã€å®è¡åšçŽ°èãšã
ãŠïŒå皮移æ€åå¿çã®ïŒçŽ°èä»åšã«ããå ç«å¿ç
ã«çŽæ¥é¢äžããŠãããããããªããã现èã¯æ¶²
æ§æäœãåæ³ããããšã¯ãªãããããã®æäœã¯èž
ç·ãšã¯ç¡é¢ä¿ã«éªšé«ã«çŽæ¥ç±æ¥ãã现èã«ããå
æ³ãããããããã®éªšé«ã«ç±æ¥ãã现èã¯ïŒ¢çŽ°è
ãšèšããããããããªãããå€ãã®æåãšã¯å¯Ÿç§°
çã«ã现èãæäœãçæããã«ã¯é©åœã«åå¿æ§
ã®ãã现èã®ååšãå¿ èŠã§ããã现èãšïŒ¢çŽ°
èã®ååã«ãããã®çæéçšã®æ©æ§ã¯æªã å®å šã«
ç解ãããŠããªãã äžè¿°ã®ããšãããäœçšå¹æãšãã芳ç¹ã«æŒããŠ
èžç·ã¯çŽ°èå ç«ã®çºçŸåã³å€ãã®æ¶²æ§æäœåå¿ã«
察ããŠå¿ èŠãªãã®ã§ãããã€é è¡æ§å¹¹çŽ°èãåå
ããŠïŒŽçŽ°èãèžç·å ã§èªå°ããããšã«ããäžèšçº
çŸåã³åå¿ç³»ã«èžç·ã¯åœ±é¿ãäžããŠãããšããã
ãšãã§ããããã®èªå°ç圱é¿ã¯èžç·ã®äžç®çŽ°èã®
åæ³ç©ãå³ã¡èžç·ãã«ã¢ã³é¡ãåªä»ãšããŠè¡ãã
ãã æŽã«ãèžç·åã³ãªã³ãç现èç³»ã®äœçšåã³äœå
ã§ã®ãªã³ãçã®åŸªç°ãç解ããã«ã¯ã幹现èã¯éªš
é«ã«çããŠè¡æ¶²ã«éã°ããŠèžç·ã«éãããšããã
ãšãæããŠããå¿ èŠããããèžç·ã®å éšã«æŒã
ãŠã幹现èã¯å ç«åŠçã«æèœãªïŒŽçŽ°èã«ååãã
现èã¯è¡æµã«ç§»è¡ã现èãšå ±ã«çš®ã ã®çµç¹ïŒ
ãªã³ã管系åã³è¡æµéã埪ç°ããã æäœãåæ³ãã身äœçŽ°èãåé è¡å¹¹çŽ°èããçº
çãããã®ã§ããã身äœçŽ°èã®ååã¯èžç·ã«ãã
決ãŸããã®ã§ã¯ãªããåŸã€ãŠã身äœçŽ°èã¯éªšé«ç±
æ¥çŽ°èå³ã¡ïŒ¢çŽ°èãšåä»ããããŠãããé³¥é¡ã«æŒ
ããŠã¯ã身äœçŽ°èã¯èžç·ã«é¡äŒŒãããã¢ããªããŠ
ã¹å¢ãšããåšå®ã§ååããããåºä¹³é¡ã§ã¯ããã¢
ããªããŠã¹å¢ã«çžåœããåšå®ã¯èŠåºãããŠããã
现èã¯éªšé«å ã§ååãããšèããããŠãããã
ã®ååãè¡ãããçççç©è³ªã¯å šãåã€ãŠããª
ãã äžè¿°ã®åŠããæ¬çºæã®ããªããããé¡ã¯äººéå
ã³åç©ã®æ²»çã«æå¹ã§ãããæ¬çºæã®ããªããã
ãé¡ã¯é è¡çµç¹ããçããé ãªã³ãç幹现èãå
åããŠèº«äœã®å ç«å¿çã«é¢äžããããšãã§ããèž
ç·ç±æ¥çŽ°èå³ã¡ïŒŽçŽ°èã«èªå°ããããšãã§ããã€
现èã®ååããèªå°ã§ããã®ã§ãããªãããã
é¡ã¯å€ãã®æ²»çäžã®çšéãæãããã®ã§ãããšæ
ãããã第ïŒã«ãæ¬çºæã®ããªããããååç©ã¯
èžç·ã®æ©èœã®å æãçš®ã®æ©èœãéè¡ã§ããã®ã§
çš®ã ã®èžç·æ©èœåéåã³å ç«åéã«é©çšã§ããã
çšéã®äž»åéã¯å 倩æ§èžç·æ¬ åŠã®ç¶æ ã§ãããã€
ãžãšãŒãžïŒDiGeorgeïŒçå矀ã®æ²»çã§ãããæ¬
çºæã®ããªããããé¡ã®æ³šå ¥ã«ãããã®æ¬ é¥åã¯
æ¬ å€±ã«æåã€ããšãã§ãããä»ã®é©çšäŸãšããŠã¯
身äœã®ïŒ¢çŽ°èååæ§æšå®ãã«ã¢ã³ã®æ¬ åŠã«äŸãç¡
ã¬ã³ãã°ãããªã³è¡çã®æ²»çã§ããããããããª
ããããé¡ã®æ³šå ¥ã«ããæ²»çããããšãã§ããã
äœæ¿åºŠã§çšããŠãéåžžã«æŽ»æ§ãããããªãããã
é¡ã®çååŠçç¹æ§ã®æ ã«ãããªããããé¡ã¯çŽ°è
å ç«åã³æ¶²æ§å ç«ã®æ²»ççåºæ¿ãå¢å€§åã¯ä¿é²
ããåŸã€ãŠçŽ°èæ§åã¯ãã€ã³ãã©ãºãäŒæç ïŒçµ
æ žïŒç©ç ïŒæ¥æ§åã³æ ¢æ§ããŒã«æ§äŒæç çã®çç©
äœäžã«ããæ ¢æ§äŒææ§ç æ°ã®æ²»çã«æå¹ã§ãã身
äœã®ç·åçå ç«ãå©æãããšããç¹ã«æŒããŠæå¹
ã§ãããæŽã«ãããªããããååç©ã¯çŽ°èåã¯æ¶²
æ§å ç«ãåé¡ã§ããåéãç¹ã«åè¿°ãã€ãžãšãŒãž
çå矀ã«æŒããåŠãå ç«ã«æ¬ æãããåéã«æå¹
ã§ãããšæããããåãããªããããé¡ã®åè¿°ç¹
æ§ã®æ ã«ãããªããããé¡ã¯è©Šéšç®¡äžã§ã®ïŒŽçŽ°è
ã®è¡šé¢æåã®çºè²ã«æå¹ã§ãããæ©èœçèœåãçº
çŸãããŠçŽ°èåè£ç©è³ªåã³æåã«å¿çãããããš
ã«æå¹ã§ããããã€çŽ°èãååãããŠïŒ¢çŽ°èã®èœ
åãé«ããŠçš®ã ã®æäœãçæãããããšãã§ã
ããçš®ã ã®æäœãçæãããããšãã§ãããæŽ
ã«ãããªããããé¡ã¯è£äœã®è¡šé¢å容äœã®çºè²ã«
ãã枬å®ãããåŠã现èãè©Šéšç®¡äžã§çºè²ãã
ãããšãã§ãããæ¬çºæã®ããªããããé¡ã¯åãŠ
ãããã³å¿çæ§ãªã³ãçã®ç¡å¶éã®å¢æ®ãçŠæ¢ã
ãã«ãæå¹ã§ããã 现èã®ç¹æ§ãçšããŠçŽ°èãå埩ãããããšã
ã§ãããšããçç©äœäžã§ã®æ§è³ªå现èã®ç¹æ§ã
çšããŠçŽ°èãå埩ãããããšãã§ãããšããçç©
äœäžã§ã®ããªããããã®æ§è³ªãããªããããã®é
èŠãªç¹æ§ã®ïŒã€ã§ããã æ¬çºæã®ããªããããé¡ã®æŽã«éèŠãªæ§è³ªã¯ã
ãªããããé¡ã¯éåžžã«äœæ¿åºŠã§éåžžã«æŽ»æ§ã§ãã
ãšããããšã§ãããå³ã¡ãããªããããé¡ã¯
10ngïŒml以äžã®æ¿åºŠã§æŽ»æ§ã§ãããçŽ0.05âïŒÎŒ
ïœïŒmlã®æ¿åºŠã§æŽ»æ§ã¯æ倧ãšãªãããã®ããªãã
ããã®æ äœãšããŠã¯ãã®æ§ãªç®çã«å¯ŸããŠéåžžçš
ããããå ¬ç¥ã®æ äœã¯ãããã䜿çšå¯èœã§ããã
äŸãã°éåžžã®å¡©æ°Žæº¶æ¶²ã䜿çšã§ããïŒãã®å Žåç
ã®è¡æž ã¢ã«ããã³çã®ã¿ã³ãã¯è³ªåžéå€ãå«ãŸã
ãŠäžèšäœæ¿åºŠã§çšããããããªãããããã¬ã©ã¹
åšå ·ã«åžçæ倱ããããšã®ãªãããã«ããããšã
奜ãŸãããæ¬çºæã®ããªããããé¡ã¯äœéïŒKgã«
察ããŠçŽ0.1mg以äžã®ç¯å²ã§æŽ»æ§ã§ããããã€ãž
ãšãŒãžçå矀ã®æ²»çã«ã¯ãããªããããé¡ã¯äœé
ïŒKgåœãçŽ0.1â10mgæäžããã°ãããäžè¬çã«
ã¯ãäžèšæäžéã¯ãããŸã§æããä»ã®çç¶åã¯ç
æ°ã®åŠçœ®ã«å¯ŸããŠãæå¹ã§ããã æ¬çºæã®ããªãããããé¡ã¯ãJournal of
American Chemical SocietyãïŒ85ïŒp2149â
2154ïŒ1963ïŒã«èšèŒãããŠãããããªã¡ãªãã€ãŒ
ã«ãã®æŠå¿µãçšããŠè£œé ããããå³ã¡ãæ°çš®ã®ä¿
è·åœ¢ã¢ããé žã段éçã«åºåœ¢æš¹èç²ã«å ±æçµåã
ããŠããçé·ããããéã«ä»å ããããšã«ããå
æãè¡ã€ãããã®æ¹æ³ã§ã¯ãè¬å€åã³å¯çç©ã¯
éåã³äžéäœã®åçµæ¶ã«ããé€å»ãããããã®æ¹
æ³ãäžè¬çã«èšãã°ãããããéã®ç¬¬ç¬¬ïŒã®ã¢ã
ãé žãåºäœé«ååã«å ±æçµåã§çµåãããåŒç¶ã
ã¢ããé žãäžåºŠã«ïŒçš®é¡ã¥ã€æ®µéçã«ä»å ããŠæ
æã®æ§é åäœãæ§æããæ¹æ³ã§ãããæåŸã«ãã
ããããåºåœ¢æ¯æäœããåé¢ããã€ä¿è·åºãé€
ãããã®æ¹æ³ã«ããã°æ£é·ããããããéã¯å®å š
ã«äžæº¶æ§ã®åºäœç²åã«çµåããŠããã®ã§éæŽæµ
ããŠè¬å€åã³å¯çç©ãé€ãã«ã¯éœåãããã ã¢ããé žé¡ã¯é©åœãªããªããŒã«çµåãããããš
ãã§ããããã®å ŽååèšããªããŒã¯äœ¿çšæº¶åªã«äž
溶æ§ã§ãªããã°ãªããåéã容æã«è¡ãããã
ãšãã§ããç©ççãªå®å®ãªåœ¢ç¶ã§ãªããã°ãªããª
ããåãããªããŒã¯ç¬¬ïŒã®ä¿è·åœ¢ã¢ããé žãå ±æ
çµåã§ç¢ºå®ã«çµåã§ããå®èœåºãå«ããã®ã§ãªã
ãã°ãªããªããçš®ã ã®ããªããŒã䜿çšå¯èœã§ãã
äŸãã°ã»ã«ããŒãºïŒããªããã«ã¢ã«ã³ãŒã«ïŒããª
ã¡ã¿ã¢ã¯ã¬ãŒããã¹ã«ãã³åããªã¹ãã¬ã³ãæã
ãããšãã§ããããæ¬çºæã§è¡ã€ãåæã§ã¯ã¹ã
ã¬ã³åã³ãžããã«ãã³ãŒã³ã®ã¯ãã«ã¡ãã«åå ±é
åäœãçšããããã 掻æ§ã§ã¯ãããåå¿ã«ã¯é¢äžãã¹ãã§ãªãã¢ã
ãé žã®åçš®å®èœåºã¯ããªããããã®å Žåé垞䜿çš
ãããå ¬ç¥ã®ä¿è·åºã«ããåæåå¿ã®éäžä¿è·ã
ãŠããããããã·ã³åã³ãªã·ã³ã®å®èœåºã¯ãæçµ
ããªããããçæç©ã«ã«æªåœ±é¿ãäžããã«æ®µéç
ä»å åå¿ã®å®äºæã«é€ãããšãã§ããä¿è·åºã«ã
ãä¿è·ããããã«ãããªã³ã°ãå®äºãããã©ãã
ãéœæ§è¢å ã®æ瀺ã«ãã決ããããã«ãã«ãªã¬ã¹
ã¢ãã³ïŒfluorescamineïŒã䜿çšãããšããç¹
ïŒFelix et alã«ããAnalyt.Biochem.ïŒ52ïŒ377ïŒ
1973åç §ïŒã«æŒããŠããªããããã®åæãåºäœå
ææ³ã®æ¹è¯æ³ã«ããè¡ããããã«ãããªã³ã°ã®å®
äºãæ瀺ãããªãå Žåã«ã¯ãαâã¢ããä¿è·è§£é€
ãè¡ãåã«åäžã®ä¿è·åœ¢ã¢ããé žãçšããŠã«ãã
ãªã³ã°ãç¹°è¿ããã åæã®äžè¬çæ¹æ³ãšããŠã¯å ãã¢ããåºãä¿è·
ãããâãªã·ã³ãã¢ãã³ãå«ãç¡æ°Žã¢ã«ã³ãŒã«
äžã§æš¹èã«å¯ŸããŠãšã¹ãã«åãããçµåããã¢ã
ãé žæš¹èãéããã¢ã«ã³ãŒã«ã次ãã§æ°Žã§æŽæµ
ãã也ç¥ããã次ãã§ãªã·ã³ã¢ããé žã®Î±âã¢ã
ãåºã®ä¿è·åºïŒäŸãã°ïœâBOCïŒå³ã¡ïœâãã
ã«ãªãã·ã«ã«ããã«ïŒãä»ã®ä¿è·åºã«åœ±é¿ãäžã
ãããšãªãé€å»ãããéé¢ã¢ããåºãæããçµå
ã¢ããé žæš¹èãä¿è·åœ¢ïŒ¬âã°ã«ã¿ãã³é žïŒå¥œãŸã
ãã¯ã¢ã«ãã¢âïœâBOCââã°ã«ã¿ãã³ïŒãš
åå¿ãããŠïŒ¬âã°ã«ã¿ãã³ãçµåããããæŽã«ã
ä¿è·åœ¢ïŒ¬âã€ãœãã€ã·ã³ïŒïŒ¬âã¢ã¹ãã©ã®ã³åã³
âããã·ã³ãçšããŠåå¿ãç¹°è¿ãå®å šãªååã
åæãããäžèšåå¿ã¯äžèšã®åŠãè¡ã€ãã
äžèšåŒãæããæ°èŠãªãã³ã¿ããããããæäŸã
ããã®ã§ããã ïŒïŒ²âHNâTYRâASNâILEâGLNâLYS
âCORâ² äžåŒã§ãã¯æ°ŽçŽ ïŒã¡ãã«ïŒãšãã«çã®C1â
C7ã®ã¢ã«ãã«ïŒããšãã«çã®C5âC12ã¢ãªãŒã«ïŒ
ã¢ã»ãã«ïŒããããªãã«çã®C1âC7ã®ã¢ã«ã«ã
ã€ã«ïŒRâ²ã¯OHïŒNH2ïŒNHR7ïŒïŒ®ïŒR7ïŒ2åã¯å¡©çŽ
ã瀺ããæã奜ãŸããããªããããé¡ã¯ïŒ²ãæ°Ž
çŽ ïŒRâ²ãOHã§ããããããé¡ã§ããã ãã³ã¿ããããé¡ã®è¬çåŠäžæºè¶³ãåŸããã³ã¿
ããããã®å¡©é¡ãåæ¬çºæã®ç¯å²ã«å«ãŸãããã
ã³ã¿ãããããšå¡©ã圢æãåŸãé žãšããŠã¯å¡©é žïŒ
èåæ°ŽçŽ é žïŒéé žçŽ é žïŒç¡é žïŒããªã·ã¢ã³é žïŒç¡«
é žïŒçé žçã®ç¡æ©é žãšè»é žïŒé ¢é žïŒããããªã³
é žïŒã°ãªã³ãŒã«é žïŒä¹³é žïŒãã«ãã³é žïŒèé žïŒã
ãã³é žïŒã³ãã¯é žïŒãã¬ã€ã³é žïŒãããŒã«é žïŒã¢
ã³ãã©ãã«é žïŒæ±ç®é žïŒããã¿ãªã³ã¹ã«ãã³é žïŒ
ã¹ã«ãã¢ãã«é žçã®ææ©é žãšãæããããšãã§ã
ãã äžèšæ§é äœã«æŒããŠããããã®ã¢ããé žæåã¯
䟿å®äžç¥å·ã§ç€ºãããããããã®ç¥å·ã¯äžèšã¢ã
ãé žã瀺ãã ã¢ããé ž ç¥ å· ïŒ¬âããã·ã³ TYR âã¢ã¹ãã©ã®ã³ ASN âã¢ã¹ãã©ã®ã³é ž ASP âã€ãœãã€ã·ã³ ILE âã»ãªã³ SER âã°ã«ã¿ãã³ GLN âãã€ã·ã³ LEU âãªã·ã³ LYS âã°ã«ã¿ãã³é ž GLU âã¹ã¬ãªãã³ THR âãã¹ããžã³ HIS âããªã³ VAL âã¢ã«ã®ãã³ ARG âã¢ã©ãã³ ALA æ¬çºæã®ããªããããé¡ã¯ïŒâã¢ããé žããã
ãé¡ã§ããããã®ããããã¯ç±³åœç¹èš±ç¬¬4002602
å·ã«é瀺ãããŠããåŠãçã®èžç·ããåé¢ããã
74âã¢ããé žããªããããã§ãããŠãããã³
ïŒUBIPïŒã«äŒŒãç¹æ§ã瀺ãããšãåã€ããæ¬çºæ
ã®ããããé¡ã¯ããã°ã©ã åäœã®æ¿åºŠã§ïŒ¢å é§äœ
现èãšåæã«ïŒŽå é§äœçŽ°èã®éžæçååãèªå°ã
ãããšãã§ããç¹ã«ãã®ç¹åŸŽããããæ¬çºæã®ã
ãªããããé¡ã¯ç±³åœç¹åŸŽç¬¬4002602å·ã«é瀺ãã
ãŠããé·éããªããããé¡ãšåæ§ã«è©Šéšç®¡äžã§å
ç«çŽ°èå é§äœçŽ°èãååãããããšãåã€ããå³
ã¡ãæ¬çºæã®ããªããããé¡ã¯äŸãããã°ã©ã å
äœã®æ¿åºŠã§ãèžç·ååæåTLåã³THYâïŒ
ïŒÎžïŒã®ç²åŸã«ãã枬å®ããããããªïŒŽå é§äœçŽ°
èãšïŒ¢çŽ°èã®èå¥ããŒã«ãŒïŒmarkerïŒã§ããè£
äœå容äœã®ç²åŸã«ãã枬å®ããããããªïŒ¢å é§äœ
现èãšã®ååãèªå°ããããšãåã€ãã æ¬çºæã®ããªããããé¡ã®çååŠçååç¹æ§ã®
éèŠæ§ãç解ããã«ã¯ãå ç«ã«é¢ããèžç·ã®æ©èœ
ã¯åºçŸ©ã«èšãã°ïŒŽçŽ°èãšèšãããèžç·ã«ç±æ¥ãã
现èå³ã¡ãªã³ãçãçæããããšã§ãããšããã
ãšãã§ããããšãéèšãã¹ãã§ããã现èã¯å
埪ç°å°ãªã³ãç貯槜ã®å€§éšåã圢æããŠããã
现èã¯å ç«åŠçç¹ç°æ§ãæããã€å®è¡åšçŽ°èãšã
ãŠïŒå皮移æ€åå¿çã®ïŒçŽ°èä»åšã«ããå ç«å¿ç
ã«çŽæ¥é¢äžããŠãããããããªããã现èã¯æ¶²
æ§æäœãåæ³ããããšã¯ãªãããããã®æäœã¯èž
ç·ãšã¯ç¡é¢ä¿ã«éªšé«ã«çŽæ¥ç±æ¥ãã现èã«ããå
æ³ãããããããã®éªšé«ã«ç±æ¥ãã现èã¯ïŒ¢çŽ°è
ãšèšããããããããªãããå€ãã®æåãšã¯å¯Ÿç§°
çã«ã现èãæäœãçæããã«ã¯é©åœã«åå¿æ§
ã®ãã现èã®ååšãå¿ èŠã§ããã现èãšïŒ¢çŽ°
èã®ååã«ãããã®çæéçšã®æ©æ§ã¯æªã å®å šã«
ç解ãããŠããªãã äžè¿°ã®ããšãããäœçšå¹æãšãã芳ç¹ã«æŒããŠ
èžç·ã¯çŽ°èå ç«ã®çºçŸåã³å€ãã®æ¶²æ§æäœåå¿ã«
察ããŠå¿ èŠãªãã®ã§ãããã€é è¡æ§å¹¹çŽ°èãåå
ããŠïŒŽçŽ°èãèžç·å ã§èªå°ããããšã«ããäžèšçº
çŸåã³åå¿ç³»ã«èžç·ã¯åœ±é¿ãäžããŠãããšããã
ãšãã§ããããã®èªå°ç圱é¿ã¯èžç·ã®äžç®çŽ°èã®
åæ³ç©ãå³ã¡èžç·ãã«ã¢ã³é¡ãåªä»ãšããŠè¡ãã
ãã æŽã«ãèžç·åã³ãªã³ãç现èç³»ã®äœçšåã³äœå
ã§ã®ãªã³ãçã®åŸªç°ãç解ããã«ã¯ã幹现èã¯éªš
é«ã«çããŠè¡æ¶²ã«éã°ããŠèžç·ã«éãããšããã
ãšãæããŠããå¿ èŠããããèžç·ã®å éšã«æŒã
ãŠã幹现èã¯å ç«åŠçã«æèœãªïŒŽçŽ°èã«ååãã
现èã¯è¡æµã«ç§»è¡ã现èãšå ±ã«çš®ã ã®çµç¹ïŒ
ãªã³ã管系åã³è¡æµéã埪ç°ããã æäœãåæ³ãã身äœçŽ°èãåé è¡å¹¹çŽ°èããçº
çãããã®ã§ããã身äœçŽ°èã®ååã¯èžç·ã«ãã
決ãŸããã®ã§ã¯ãªããåŸã€ãŠã身äœçŽ°èã¯éªšé«ç±
æ¥çŽ°èå³ã¡ïŒ¢çŽ°èãšåä»ããããŠãããé³¥é¡ã«æŒ
ããŠã¯ã身äœçŽ°èã¯èžç·ã«é¡äŒŒãããã¢ããªããŠ
ã¹å¢ãšããåšå®ã§ååããããåºä¹³é¡ã§ã¯ããã¢
ããªããŠã¹å¢ã«çžåœããåšå®ã¯èŠåºãããŠããã
现èã¯éªšé«å ã§ååãããšèããããŠãããã
ã®ååãè¡ãããçççç©è³ªã¯å šãåã€ãŠããª
ãã äžè¿°ã®åŠããæ¬çºæã®ããªããããé¡ã¯äººéå
ã³åç©ã®æ²»çã«æå¹ã§ãããæ¬çºæã®ããªããã
ãé¡ã¯é è¡çµç¹ããçããé ãªã³ãç幹现èãå
åããŠèº«äœã®å ç«å¿çã«é¢äžããããšãã§ããèž
ç·ç±æ¥çŽ°èå³ã¡ïŒŽçŽ°èã«èªå°ããããšãã§ããã€
现èã®ååããèªå°ã§ããã®ã§ãããªãããã
é¡ã¯å€ãã®æ²»çäžã®çšéãæãããã®ã§ãããšæ
ãããã第ïŒã«ãæ¬çºæã®ããªããããååç©ã¯
èžç·ã®æ©èœã®å æãçš®ã®æ©èœãéè¡ã§ããã®ã§
çš®ã ã®èžç·æ©èœåéåã³å ç«åéã«é©çšã§ããã
çšéã®äž»åéã¯å 倩æ§èžç·æ¬ åŠã®ç¶æ ã§ãããã€
ãžãšãŒãžïŒDiGeorgeïŒçå矀ã®æ²»çã§ãããæ¬
çºæã®ããªããããé¡ã®æ³šå ¥ã«ãããã®æ¬ é¥åã¯
æ¬ å€±ã«æåã€ããšãã§ãããä»ã®é©çšäŸãšããŠã¯
身äœã®ïŒ¢çŽ°èååæ§æšå®ãã«ã¢ã³ã®æ¬ åŠã«äŸãç¡
ã¬ã³ãã°ãããªã³è¡çã®æ²»çã§ããããããããª
ããããé¡ã®æ³šå ¥ã«ããæ²»çããããšãã§ããã
äœæ¿åºŠã§çšããŠãéåžžã«æŽ»æ§ãããããªãããã
é¡ã®çååŠçç¹æ§ã®æ ã«ãããªããããé¡ã¯çŽ°è
å ç«åã³æ¶²æ§å ç«ã®æ²»ççåºæ¿ãå¢å€§åã¯ä¿é²
ããåŸã€ãŠçŽ°èæ§åã¯ãã€ã³ãã©ãºãäŒæç ïŒçµ
æ žïŒç©ç ïŒæ¥æ§åã³æ ¢æ§ããŒã«æ§äŒæç çã®çç©
äœäžã«ããæ ¢æ§äŒææ§ç æ°ã®æ²»çã«æå¹ã§ãã身
äœã®ç·åçå ç«ãå©æãããšããç¹ã«æŒããŠæå¹
ã§ãããæŽã«ãããªããããååç©ã¯çŽ°èåã¯æ¶²
æ§å ç«ãåé¡ã§ããåéãç¹ã«åè¿°ãã€ãžãšãŒãž
çå矀ã«æŒããåŠãå ç«ã«æ¬ æãããåéã«æå¹
ã§ãããšæããããåãããªããããé¡ã®åè¿°ç¹
æ§ã®æ ã«ãããªããããé¡ã¯è©Šéšç®¡äžã§ã®ïŒŽçŽ°è
ã®è¡šé¢æåã®çºè²ã«æå¹ã§ãããæ©èœçèœåãçº
çŸãããŠçŽ°èåè£ç©è³ªåã³æåã«å¿çãããããš
ã«æå¹ã§ããããã€çŽ°èãååãããŠïŒ¢çŽ°èã®èœ
åãé«ããŠçš®ã ã®æäœãçæãããããšãã§ã
ããçš®ã ã®æäœãçæãããããšãã§ãããæŽ
ã«ãããªããããé¡ã¯è£äœã®è¡šé¢å容äœã®çºè²ã«
ãã枬å®ãããåŠã现èãè©Šéšç®¡äžã§çºè²ãã
ãããšãã§ãããæ¬çºæã®ããªããããé¡ã¯åãŠ
ãããã³å¿çæ§ãªã³ãçã®ç¡å¶éã®å¢æ®ãçŠæ¢ã
ãã«ãæå¹ã§ããã 现èã®ç¹æ§ãçšããŠçŽ°èãå埩ãããããšã
ã§ãããšããçç©äœäžã§ã®æ§è³ªå现èã®ç¹æ§ã
çšããŠçŽ°èãå埩ãããããšãã§ãããšããçç©
äœäžã§ã®ããªããããã®æ§è³ªãããªããããã®é
èŠãªç¹æ§ã®ïŒã€ã§ããã æ¬çºæã®ããªããããé¡ã®æŽã«éèŠãªæ§è³ªã¯ã
ãªããããé¡ã¯éåžžã«äœæ¿åºŠã§éåžžã«æŽ»æ§ã§ãã
ãšããããšã§ãããå³ã¡ãããªããããé¡ã¯
10ngïŒml以äžã®æ¿åºŠã§æŽ»æ§ã§ãããçŽ0.05âïŒÎŒ
ïœïŒmlã®æ¿åºŠã§æŽ»æ§ã¯æ倧ãšãªãããã®ããªãã
ããã®æ äœãšããŠã¯ãã®æ§ãªç®çã«å¯ŸããŠéåžžçš
ããããå ¬ç¥ã®æ äœã¯ãããã䜿çšå¯èœã§ããã
äŸãã°éåžžã®å¡©æ°Žæº¶æ¶²ã䜿çšã§ããïŒãã®å Žåç
ã®è¡æž ã¢ã«ããã³çã®ã¿ã³ãã¯è³ªåžéå€ãå«ãŸã
ãŠäžèšäœæ¿åºŠã§çšããããããªãããããã¬ã©ã¹
åšå ·ã«åžçæ倱ããããšã®ãªãããã«ããããšã
奜ãŸãããæ¬çºæã®ããªããããé¡ã¯äœéïŒKgã«
察ããŠçŽ0.1mg以äžã®ç¯å²ã§æŽ»æ§ã§ããããã€ãž
ãšãŒãžçå矀ã®æ²»çã«ã¯ãããªããããé¡ã¯äœé
ïŒKgåœãçŽ0.1â10mgæäžããã°ãããäžè¬çã«
ã¯ãäžèšæäžéã¯ãããŸã§æããä»ã®çç¶åã¯ç
æ°ã®åŠçœ®ã«å¯ŸããŠãæå¹ã§ããã æ¬çºæã®ããªãããããé¡ã¯ãJournal of
American Chemical SocietyãïŒ85ïŒp2149â
2154ïŒ1963ïŒã«èšèŒãããŠãããããªã¡ãªãã€ãŒ
ã«ãã®æŠå¿µãçšããŠè£œé ããããå³ã¡ãæ°çš®ã®ä¿
è·åœ¢ã¢ããé žã段éçã«åºåœ¢æš¹èç²ã«å ±æçµåã
ããŠããçé·ããããéã«ä»å ããããšã«ããå
æãè¡ã€ãããã®æ¹æ³ã§ã¯ãè¬å€åã³å¯çç©ã¯
éåã³äžéäœã®åçµæ¶ã«ããé€å»ãããããã®æ¹
æ³ãäžè¬çã«èšãã°ãããããéã®ç¬¬ç¬¬ïŒã®ã¢ã
ãé žãåºäœé«ååã«å ±æçµåã§çµåãããåŒç¶ã
ã¢ããé žãäžåºŠã«ïŒçš®é¡ã¥ã€æ®µéçã«ä»å ããŠæ
æã®æ§é åäœãæ§æããæ¹æ³ã§ãããæåŸã«ãã
ããããåºåœ¢æ¯æäœããåé¢ããã€ä¿è·åºãé€
ãããã®æ¹æ³ã«ããã°æ£é·ããããããéã¯å®å š
ã«äžæº¶æ§ã®åºäœç²åã«çµåããŠããã®ã§éæŽæµ
ããŠè¬å€åã³å¯çç©ãé€ãã«ã¯éœåãããã ã¢ããé žé¡ã¯é©åœãªããªããŒã«çµåãããããš
ãã§ããããã®å ŽååèšããªããŒã¯äœ¿çšæº¶åªã«äž
溶æ§ã§ãªããã°ãªããåéã容æã«è¡ãããã
ãšãã§ããç©ççãªå®å®ãªåœ¢ç¶ã§ãªããã°ãªããª
ããåãããªããŒã¯ç¬¬ïŒã®ä¿è·åœ¢ã¢ããé žãå ±æ
çµåã§ç¢ºå®ã«çµåã§ããå®èœåºãå«ããã®ã§ãªã
ãã°ãªããªããçš®ã ã®ããªããŒã䜿çšå¯èœã§ãã
äŸãã°ã»ã«ããŒãºïŒããªããã«ã¢ã«ã³ãŒã«ïŒããª
ã¡ã¿ã¢ã¯ã¬ãŒããã¹ã«ãã³åããªã¹ãã¬ã³ãæã
ãããšãã§ããããæ¬çºæã§è¡ã€ãåæã§ã¯ã¹ã
ã¬ã³åã³ãžããã«ãã³ãŒã³ã®ã¯ãã«ã¡ãã«åå ±é
åäœãçšããããã 掻æ§ã§ã¯ãããåå¿ã«ã¯é¢äžãã¹ãã§ãªãã¢ã
ãé žã®åçš®å®èœåºã¯ããªããããã®å Žåé垞䜿çš
ãããå ¬ç¥ã®ä¿è·åºã«ããåæåå¿ã®éäžä¿è·ã
ãŠããããããã·ã³åã³ãªã·ã³ã®å®èœåºã¯ãæçµ
ããªããããçæç©ã«ã«æªåœ±é¿ãäžããã«æ®µéç
ä»å åå¿ã®å®äºæã«é€ãããšãã§ããä¿è·åºã«ã
ãä¿è·ããããã«ãããªã³ã°ãå®äºãããã©ãã
ãéœæ§è¢å ã®æ瀺ã«ãã決ããããã«ãã«ãªã¬ã¹
ã¢ãã³ïŒfluorescamineïŒã䜿çšãããšããç¹
ïŒFelix et alã«ããAnalyt.Biochem.ïŒ52ïŒ377ïŒ
1973åç §ïŒã«æŒããŠããªããããã®åæãåºäœå
ææ³ã®æ¹è¯æ³ã«ããè¡ããããã«ãããªã³ã°ã®å®
äºãæ瀺ãããªãå Žåã«ã¯ãαâã¢ããä¿è·è§£é€
ãè¡ãåã«åäžã®ä¿è·åœ¢ã¢ããé žãçšããŠã«ãã
ãªã³ã°ãç¹°è¿ããã åæã®äžè¬çæ¹æ³ãšããŠã¯å ãã¢ããåºãä¿è·
ãããâãªã·ã³ãã¢ãã³ãå«ãç¡æ°Žã¢ã«ã³ãŒã«
äžã§æš¹èã«å¯ŸããŠãšã¹ãã«åãããçµåããã¢ã
ãé žæš¹èãéããã¢ã«ã³ãŒã«ã次ãã§æ°Žã§æŽæµ
ãã也ç¥ããã次ãã§ãªã·ã³ã¢ããé žã®Î±âã¢ã
ãåºã®ä¿è·åºïŒäŸãã°ïœâBOCïŒå³ã¡ïœâãã
ã«ãªãã·ã«ã«ããã«ïŒãä»ã®ä¿è·åºã«åœ±é¿ãäžã
ãããšãªãé€å»ãããéé¢ã¢ããåºãæããçµå
ã¢ããé žæš¹èãä¿è·åœ¢ïŒ¬âã°ã«ã¿ãã³é žïŒå¥œãŸã
ãã¯ã¢ã«ãã¢âïœâBOCââã°ã«ã¿ãã³ïŒãš
åå¿ãããŠïŒ¬âã°ã«ã¿ãã³ãçµåããããæŽã«ã
ä¿è·åœ¢ïŒ¬âã€ãœãã€ã·ã³ïŒïŒ¬âã¢ã¹ãã©ã®ã³åã³
âããã·ã³ãçšããŠåå¿ãç¹°è¿ãå®å šãªååã
åæãããäžèšåå¿ã¯äžèšã®åŠãè¡ã€ãã
æ¬çºæã®ããªãããããåæããããã«ãäžèš
ç©è³ªãè³Œå ¥ããã αâBOCââã°ã«ã¿ãã³ââãããã
ãšãã«âãšã¹ã㫠αâBOCâεâïŒâã¯ãã«âãã³ãžã«ãªã
ã·ã«ã«ããã«ââãªã·ã³ αâBOCâã¢ã¹ãã©ã®ã³ αâBOCââã€ãœãã€ã·ã³ αâBOCââïŒïŒïŒâãžã¯ãã«ãã³ã¶ã«
ââããã·ã³ äžèšè¬å€ã«æŒããŠãBOCã¯ïœâããã«ãªãã·
ã«ã«ããã«ã瀺ããã¢ããé žã®é次åå¿ã«éããŠ
çšããè©Šè¬ïŒãžã·ã¯ãããã·ã«ã«ãŒããžã€ããïŒ
ãã«ãªã¬ã¹ã¢ãã³ïŒfluorescamineïŒåã³æš¹èã
åžè²©åãè³Œå ¥ããã 䜿çšããæš¹èã¯ç²åŸ200ã400ã¡ãã·ãŠã®ããªã¹
ãã¬ã³ãžããã«ãã³ãŒã³æš¹èã§ãããïŒïŒ ã®ãžã
ãã«ãã³ãŒã³ãšæš¹èïŒïœåœã0.75ããªã¢ã«ã®ã¯ã
ã©ã€ããå«æããŠããã ããªãããããåæããã«åœããïŒããªã¢ã«ã®
αâBOCâεâïŒâã¯ãã«ãã³ãžã«ãªãã·ã«ã«
ããã«ââãªã·ã³ãïŒããªã¢ã«ã®ããªãšãã«ã¢
ãã³ãå«ãç¡æ°Žã¢ã«ã³ãŒã«äž80âã§24æéåŠçã
ãŠïŒããªã¢ã«ã®ã¯ããã¡ãã«åæš¹èã«ãšã¹ãã«å
ãããåŸãããçµåã¢ããé žæš¹èãéããç¡æ°Ž
ã¢ã«ã³ãŒã«ã§æŽæµããã€ä¹Ÿç¥ããã次ãã§ãæ®ã
ã®Î±âBOCã¢ããé žãåæ§ã«ããŠããããâæš¹
èã®ä¿è·è§£é€ãããαâã¢ããåºã«é 次çµåã
ããçŽæ¥çµåããŠããαâBOCââã°ã«ã¿ã
ã³ââãããããšãã«ãšã¹ãã«ä»¥å€ã¯åœéã®ãž
ã·ã¯ãããã·ã«ã«ãŒããžã€ãããçšããŠæ¬çºæã®
ããªãããããåæãããåã«ãããªã³ã°åå¿
åŸãå°éã®æš¹èããã«ãªã¬ã¹ã¢ãã³ã§è©Šéšããã
ãéœæ§è¢å ãšãªã€ãå Žåã«ã¯ã«ãããªã³ã°ã¯äžå®
å šã§ãããšããŠåäžã®ä¿è·åœ¢ã¢ããé žãçšããŠå
å¿ãç¹°è¿ãããæ°åã«ãããªã³ã°åå¿ãè¡ã€ãçµ
æãäžéäœãã³ã¿ããããâæš¹èãåŸãããã ãã®ãã³ã³ã¿ããããâæš¹èã®åå²ãšä¿è·åºã®
é€å»ãïŒâ60åéç¡æ°Žããã«æ°ŽçŽ ãçšããŠã±ã«ã
åå²è£ 眮ïŒPeninsula Lab.Inc.補ïŒã§è¡ãããã®
å Žåã¹ã«ãã³ãžã€ãŒãšããŠããããâæš¹èïŒïœã«
察ããŠ1.2mlã®ã¢ããœãŒã«ãçšãããããããæ··
åç©ãåçµç空也ç¥ããç¡æ°ŽãšãŒãã«ã§æŽæµã
ãããã®ããããã1Né ¢é žäžïœâïŒããªâã²ã«
ïŒBioâGelïŒäžã«æ æããŠã¯ãããã°ã©ãåæã«
ä»ãããåŸãããããªããããã¯çŽåºŠ94ïŒ ã§äžèš
æ§é ãæããããšãåã€ãã H2NâTYRâASNâILEâGLNâLYSâCOOH ãå®æœäŸ ïŒã äžèšããªããããã®æŽ»æ§åã³ç¹æ§ã調ã¹ããã
ã«ã建康ãªçåŸïŒãïŒé±éã®nuïŒnuããŠã¹ã®äž¡
æ§ã«ã€ããŠè©Šéšãè¡ã€ããããŠã¹ã¯BALBïŒïœè
å°ïŒThyâ1.2 è¡šé¢æåã瀺ãèžç·çŽ°èïŒã§é£Œ
è²ãããã€éåžžã®æ¡ä»¶äžã«ç¶æããããæè¡æž ã«
é¢ããŠã¯ãæThyâ1.2è¡æž ãThyâïŒåæããŠ
ã¹ã§èª¿è£œããã Thyâ1+T现èåã¯CR+B现èã®ååã®è©Šéšç®¡
äžèªå°ãè¡ãããã«ãè©Šéšç®¡äžã§åèžç·çŽ°è
ïŒprothymocyteïŒããã®èžç·çŽ°èã®ååèªå°ãã³
ã ãåã³ãã€ã¹ïŒKomuro ïŒBoyseïŒã«ããèš
èŒãããæ¹æ³ïŒLancetïŒïŒïŒ740ïŒ1973ïŒã«æºã
ãŠè¡ã€ãããã®æ¹æ³ã§ã¯Thyâ1.2ã®ç²åŸã现
èååã®ç®å®ãšããŠå©çšããŠãããäžæ¹ãè©Šéšç®¡
äžã§ã®CR-B现èå é§äœããã®CR+B现èãžã®å
åã®èªå°ãèžç·çŽ°èã®å Žåãšåæ§ã®æ¡ä»¶äžã§è¡ã€
ããããã®å Žååæã®èŠæºãšããŠãããã®æäœå
ã³éå解æ§ã®è£äœãå€å°åéããçšåºŠã®éå¡è¢«ã
ããçŸã®èµ€è¡çãçµåããCR+B现èã®èœåãçš
ãããäžé£ç¶ãªçã®è¡æž ã¢ã«ããã³åŸé äžã§åå¥
ãããå¥åº·ãªnuïŒnuããŠã¹ã®èŸè现è矀ãäž¡å
é§äœïŒThyâ1-åã³CR-ïŒæºãšããŠçšããããã
ã¯åèšçŽ°è矀ã¯æ®ãã©åã¯å šãThyâ1+现èãå«
ãŸããããCR+现èã®æ°ã¯å°ãã§ãããšããçç±
ã«ããã ãã®çµæããã®ããªããããã¯ïŒŽãªã³ãçåã³
è£äœå容äœïŒCR+ïŒïŒ¢ãªã³ãçã®ååãèªå°ãã
ãšããç¹ã«æŒããŠãŠãããã³ãšåæ§ã®äœçšéžææ§
ã瀺ããããã®ãã³ã¿ããããã¯10ngâïŒÎŒ
ïœïŒmlã®æ¿åºŠç¯å²ã§Thyâ1+T现èã®ååãèªå°
ããã€10ngâïŒÎŒïœïŒmlã®æ¿åºŠç¯å²ã§CR+B现è
ã®ååãèªå°ããã ãå®æœäŸ ïŒã å®æœäŸïŒã®ãã³ã¿ããããã®ã¢ããåèªå°äœã
åŸãããã«ãåºæ¿ãšããŠãã³ãºãããªã«ã¢ãã³ã
çšããŠåè¿°ã®J.Rivierçã®æ¹æ³ã«ããä¿è·ããã
ãã³ã¿ãããããåæããã次ãã§åŒåæ°ŽçŽ ãå©
çšããŠæš¹èåºæ¿ã«ä»çããŠããä¿è·ãã³ã¿ããã
ããéè£åé¢ããŠäžèšåŒã®ã¢ããåèªå°äœãåŸ
ãã H2NâTYRâASN ILEâGLNâLYSâCONH2 äžèšèªå°äœãåå®ããããã«ãèå±€ã¯ãããã°
ã©ãæ³åã³é»æ°æ³³åæ³ãçšããŠäžèšçµæãåŸãã èå±€ã¯ãããã°ã©ãæ³ è©ŠæïŒ30ÎŒïœ ã·ãªã«ã²ã«ïŒããªã³ã¯ãã³ã¬ã©ã¹æ¿ïŒïŒÃ20
cmïŒåã0.25mmïŒ ïŒ²ïŒ ïœïŒïœâãã¿ããŒã«ïŒããªãžã³ïŒé ¢é ž
ïŒHOAcïŒ ïŒæ°Ž 30ïŒ15ïŒïŒïŒ12 ïŒïŒé ¢é žãšãã«ïŒEtoAcïŒïŒããªãžã³ïŒé ¢é ž ïŒæ°Ž ïŒïŒïŒïŒïŒïŒïŒ ïŒïŒé ¢é žãšãã«ïŒïœâãã¿ããŒã«ïŒé ¢é ž ïŒæ°Ž ïŒïŒïŒïŒïŒïŒïŒ ã¹ãã¬ãŒè©Šè¬ïŒããŠãªè©Šè¬ïŒãã³ãããªã³åã³
I2
ç©è³ªãè³Œå ¥ããã αâBOCââã°ã«ã¿ãã³ââãããã
ãšãã«âãšã¹ã㫠αâBOCâεâïŒâã¯ãã«âãã³ãžã«ãªã
ã·ã«ã«ããã«ââãªã·ã³ αâBOCâã¢ã¹ãã©ã®ã³ αâBOCââã€ãœãã€ã·ã³ αâBOCââïŒïŒïŒâãžã¯ãã«ãã³ã¶ã«
ââããã·ã³ äžèšè¬å€ã«æŒããŠãBOCã¯ïœâããã«ãªãã·
ã«ã«ããã«ã瀺ããã¢ããé žã®é次åå¿ã«éããŠ
çšããè©Šè¬ïŒãžã·ã¯ãããã·ã«ã«ãŒããžã€ããïŒ
ãã«ãªã¬ã¹ã¢ãã³ïŒfluorescamineïŒåã³æš¹èã
åžè²©åãè³Œå ¥ããã 䜿çšããæš¹èã¯ç²åŸ200ã400ã¡ãã·ãŠã®ããªã¹
ãã¬ã³ãžããã«ãã³ãŒã³æš¹èã§ãããïŒïŒ ã®ãžã
ãã«ãã³ãŒã³ãšæš¹èïŒïœåœã0.75ããªã¢ã«ã®ã¯ã
ã©ã€ããå«æããŠããã ããªãããããåæããã«åœããïŒããªã¢ã«ã®
αâBOCâεâïŒâã¯ãã«ãã³ãžã«ãªãã·ã«ã«
ããã«ââãªã·ã³ãïŒããªã¢ã«ã®ããªãšãã«ã¢
ãã³ãå«ãç¡æ°Žã¢ã«ã³ãŒã«äž80âã§24æéåŠçã
ãŠïŒããªã¢ã«ã®ã¯ããã¡ãã«åæš¹èã«ãšã¹ãã«å
ãããåŸãããçµåã¢ããé žæš¹èãéããç¡æ°Ž
ã¢ã«ã³ãŒã«ã§æŽæµããã€ä¹Ÿç¥ããã次ãã§ãæ®ã
ã®Î±âBOCã¢ããé žãåæ§ã«ããŠããããâæš¹
èã®ä¿è·è§£é€ãããαâã¢ããåºã«é 次çµåã
ããçŽæ¥çµåããŠããαâBOCââã°ã«ã¿ã
ã³ââãããããšãã«ãšã¹ãã«ä»¥å€ã¯åœéã®ãž
ã·ã¯ãããã·ã«ã«ãŒããžã€ãããçšããŠæ¬çºæã®
ããªãããããåæãããåã«ãããªã³ã°åå¿
åŸãå°éã®æš¹èããã«ãªã¬ã¹ã¢ãã³ã§è©Šéšããã
ãéœæ§è¢å ãšãªã€ãå Žåã«ã¯ã«ãããªã³ã°ã¯äžå®
å šã§ãããšããŠåäžã®ä¿è·åœ¢ã¢ããé žãçšããŠå
å¿ãç¹°è¿ãããæ°åã«ãããªã³ã°åå¿ãè¡ã€ãçµ
æãäžéäœãã³ã¿ããããâæš¹èãåŸãããã ãã®ãã³ã³ã¿ããããâæš¹èã®åå²ãšä¿è·åºã®
é€å»ãïŒâ60åéç¡æ°Žããã«æ°ŽçŽ ãçšããŠã±ã«ã
åå²è£ 眮ïŒPeninsula Lab.Inc.補ïŒã§è¡ãããã®
å Žåã¹ã«ãã³ãžã€ãŒãšããŠããããâæš¹èïŒïœã«
察ããŠ1.2mlã®ã¢ããœãŒã«ãçšãããããããæ··
åç©ãåçµç空也ç¥ããç¡æ°ŽãšãŒãã«ã§æŽæµã
ãããã®ããããã1Né ¢é žäžïœâïŒããªâã²ã«
ïŒBioâGelïŒäžã«æ æããŠã¯ãããã°ã©ãåæã«
ä»ãããåŸãããããªããããã¯çŽåºŠ94ïŒ ã§äžèš
æ§é ãæããããšãåã€ãã H2NâTYRâASNâILEâGLNâLYSâCOOH ãå®æœäŸ ïŒã äžèšããªããããã®æŽ»æ§åã³ç¹æ§ã調ã¹ããã
ã«ã建康ãªçåŸïŒãïŒé±éã®nuïŒnuããŠã¹ã®äž¡
æ§ã«ã€ããŠè©Šéšãè¡ã€ããããŠã¹ã¯BALBïŒïœè
å°ïŒThyâ1.2 è¡šé¢æåã瀺ãèžç·çŽ°èïŒã§é£Œ
è²ãããã€éåžžã®æ¡ä»¶äžã«ç¶æããããæè¡æž ã«
é¢ããŠã¯ãæThyâ1.2è¡æž ãThyâïŒåæããŠ
ã¹ã§èª¿è£œããã Thyâ1+T现èåã¯CR+B现èã®ååã®è©Šéšç®¡
äžèªå°ãè¡ãããã«ãè©Šéšç®¡äžã§åèžç·çŽ°è
ïŒprothymocyteïŒããã®èžç·çŽ°èã®ååèªå°ãã³
ã ãåã³ãã€ã¹ïŒKomuro ïŒBoyseïŒã«ããèš
èŒãããæ¹æ³ïŒLancetïŒïŒïŒ740ïŒ1973ïŒã«æºã
ãŠè¡ã€ãããã®æ¹æ³ã§ã¯Thyâ1.2ã®ç²åŸã现
èååã®ç®å®ãšããŠå©çšããŠãããäžæ¹ãè©Šéšç®¡
äžã§ã®CR-B现èå é§äœããã®CR+B现èãžã®å
åã®èªå°ãèžç·çŽ°èã®å Žåãšåæ§ã®æ¡ä»¶äžã§è¡ã€
ããããã®å Žååæã®èŠæºãšããŠãããã®æäœå
ã³éå解æ§ã®è£äœãå€å°åéããçšåºŠã®éå¡è¢«ã
ããçŸã®èµ€è¡çãçµåããCR+B现èã®èœåãçš
ãããäžé£ç¶ãªçã®è¡æž ã¢ã«ããã³åŸé äžã§åå¥
ãããå¥åº·ãªnuïŒnuããŠã¹ã®èŸè现è矀ãäž¡å
é§äœïŒThyâ1-åã³CR-ïŒæºãšããŠçšããããã
ã¯åèšçŽ°è矀ã¯æ®ãã©åã¯å šãThyâ1+现èãå«
ãŸããããCR+现èã®æ°ã¯å°ãã§ãããšããçç±
ã«ããã ãã®çµæããã®ããªããããã¯ïŒŽãªã³ãçåã³
è£äœå容äœïŒCR+ïŒïŒ¢ãªã³ãçã®ååãèªå°ãã
ãšããç¹ã«æŒããŠãŠãããã³ãšåæ§ã®äœçšéžææ§
ã瀺ããããã®ãã³ã¿ããããã¯10ngâïŒÎŒ
ïœïŒmlã®æ¿åºŠç¯å²ã§Thyâ1+T现èã®ååãèªå°
ããã€10ngâïŒÎŒïœïŒmlã®æ¿åºŠç¯å²ã§CR+B现è
ã®ååãèªå°ããã ãå®æœäŸ ïŒã å®æœäŸïŒã®ãã³ã¿ããããã®ã¢ããåèªå°äœã
åŸãããã«ãåºæ¿ãšããŠãã³ãºãããªã«ã¢ãã³ã
çšããŠåè¿°ã®J.Rivierçã®æ¹æ³ã«ããä¿è·ããã
ãã³ã¿ãããããåæããã次ãã§åŒåæ°ŽçŽ ãå©
çšããŠæš¹èåºæ¿ã«ä»çããŠããä¿è·ãã³ã¿ããã
ããéè£åé¢ããŠäžèšåŒã®ã¢ããåèªå°äœãåŸ
ãã H2NâTYRâASN ILEâGLNâLYSâCONH2 äžèšèªå°äœãåå®ããããã«ãèå±€ã¯ãããã°
ã©ãæ³åã³é»æ°æ³³åæ³ãçšããŠäžèšçµæãåŸãã èå±€ã¯ãããã°ã©ãæ³ è©ŠæïŒ30ÎŒïœ ã·ãªã«ã²ã«ïŒããªã³ã¯ãã³ã¬ã©ã¹æ¿ïŒïŒÃ20
cmïŒåã0.25mmïŒ ïŒ²ïŒ ïœïŒïœâãã¿ããŒã«ïŒããªãžã³ïŒé ¢é ž
ïŒHOAcïŒ ïŒæ°Ž 30ïŒ15ïŒïŒïŒ12 ïŒïŒé ¢é žãšãã«ïŒEtoAcïŒïŒããªãžã³ïŒé ¢é ž ïŒæ°Ž ïŒïŒïŒïŒïŒïŒïŒ ïŒïŒé ¢é žãšãã«ïŒïœâãã¿ããŒã«ïŒé ¢é ž ïŒæ°Ž ïŒïŒïŒïŒïŒïŒïŒ ã¹ãã¬ãŒè©Šè¬ïŒããŠãªè©Šè¬ïŒãã³ãããªã³åã³
I2
ãè¡šã
é»æ°æ³³åæ³
ã¯ãããã³ïŒmmåçŽïŒ11.5cmÃ56.5mmïŒ
è©ŠæïŒ100ÎŒïœ
PH5.6ïŒããªãžã³âã¢ã»ããŒãç·©è¡æº¶æ¶²
1000VïŒïŒæé
ã¹ãã¬ãŒè©Šè¬ïŒããŠãªè©Šè¬åã³ãã³ãããªã³
å®æœäŸïŒã®ã¢ããåãã³ã¿ããããã¯ãïŒïŒ
ã
ãŠããŒïŒTwomeyïŒæº¶æ¶²äžïŒÎŒïœïŒmlã®æ¿åºŠã§çš
ããæå®æœäŸïŒã®åºæ¬åœ¢ãã³ã¿ããããã«å¹æµã
ã掻æ§ã瀺ããããã®èšèŒãå å ¥ããã 以äžãæ¬çºæã¯æŽ»æ§éšäœãšããŠåè¿°ã®ç¹ç°ãªã¢
ããé žæ§é åäœãæããæ°èŠãªããªãããããæ
äŸãããã®ã§ããããã®ããªããããã¯ãèžç·å
åæåTLåã³THYâïŒïŒÎžïŒã®ç²åŸã«ãã枬å®
ããããããªïŒŽâå é§äœçŽ°èãšïŒ¢çŽ°èã®èå¥ã®ç®
å®ã§ããè£äœã®å容äœã®ç²åŸã«ãã枬å®ãããã
ããªïŒ¢âå é§äœçŽ°èãšãååããããšãã§ããã
åŸã€ãŠãããããã¯èžç·æ©èœåã³å ç«åéãäŸã
ã°å 倩æ§èžç·æ¬ æã®æ²»çãã«æå¹ã§ããããã®ã
ãããã¯éåžžã«äœæ¿åºŠã§æŽ»æ§ã§ããã æ¬çºæã¯ããã€ãã®å¥œãŸããå®æœæ æ§ã«ã€ããŠ
説æããŠãããããããã®æ æ§ã«æ¬çºæãéå®ã
ãããã®ã§ãªãã
ãŠããŒïŒTwomeyïŒæº¶æ¶²äžïŒÎŒïœïŒmlã®æ¿åºŠã§çš
ããæå®æœäŸïŒã®åºæ¬åœ¢ãã³ã¿ããããã«å¹æµã
ã掻æ§ã瀺ããããã®èšèŒãå å ¥ããã 以äžãæ¬çºæã¯æŽ»æ§éšäœãšããŠåè¿°ã®ç¹ç°ãªã¢
ããé žæ§é åäœãæããæ°èŠãªããªãããããæ
äŸãããã®ã§ããããã®ããªããããã¯ãèžç·å
åæåTLåã³THYâïŒïŒÎžïŒã®ç²åŸã«ãã枬å®
ããããããªïŒŽâå é§äœçŽ°èãšïŒ¢çŽ°èã®èå¥ã®ç®
å®ã§ããè£äœã®å容äœã®ç²åŸã«ãã枬å®ãããã
ããªïŒ¢âå é§äœçŽ°èãšãååããããšãã§ããã
åŸã€ãŠãããããã¯èžç·æ©èœåã³å ç«åéãäŸã
ã°å 倩æ§èžç·æ¬ æã®æ²»çãã«æå¹ã§ããããã®ã
ãããã¯éåžžã«äœæ¿åºŠã§æŽ»æ§ã§ããã æ¬çºæã¯ããã€ãã®å¥œãŸããå®æœæ æ§ã«ã€ããŠ
説æããŠãããããããã®æ æ§ã«æ¬çºæãéå®ã
ãããã®ã§ãªãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ äžèšåŒã§è¡šãããããã³ã¿ããããåã³ãã®
å¡©é¡ã§ãã€ãŠã H2NâTYRâASN ILEâGLNâLYSâCORâ² äžèšåŒã«ãããŠRâ²ãOHåºåã¯NH2åºã§ããã
ãšãç¹åŸŽãšãããã³ã¿ããããååç©ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85177877A | 1977-11-15 | 1977-11-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5476522A JPS5476522A (en) | 1979-06-19 |
| JPS6149320B2 true JPS6149320B2 (ja) | 1986-10-29 |
Family
ID=25311658
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1956878A Granted JPS5476522A (en) | 1977-11-15 | 1978-02-22 | Novel pentapeptides and manufacture |
| JP60111321A Granted JPS6150999A (ja) | 1977-11-15 | 1985-05-22 | ãã³ã¿ããããååç©ã®è£œé æ¹æ³ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60111321A Granted JPS6150999A (ja) | 1977-11-15 | 1985-05-22 | ãã³ã¿ããããååç©ã®è£œé æ¹æ³ |
Country Status (7)
| Country | Link |
|---|---|
| JP (2) | JPS5476522A (ja) |
| BE (1) | BE864122A (ja) |
| CA (1) | CA1105923A (ja) |
| CH (1) | CH640217A5 (ja) |
| DE (1) | DE2804567C2 (ja) |
| FR (1) | FR2408581A1 (ja) |
| SE (1) | SE446866B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215112A (en) * | 1979-03-14 | 1980-07-29 | Ortho Pharmaceutical Corporation | Tripeptides and methods |
| US4215111A (en) * | 1979-03-14 | 1980-07-29 | Ortho Pharmaceutical Corporation | Peptides having ubiquitin-like activity |
| DE2938420A1 (de) * | 1979-09-22 | 1981-04-09 | Hoechst Ag, 6000 Frankfurt | Neue peptide und verfahren zu ihrer herstellung |
| US4426324A (en) * | 1979-09-28 | 1984-01-17 | Hoffmann-La Roche Inc. | Immunopotentiating peptides |
| JPH0528542U (ja) * | 1991-04-03 | 1993-04-16 | åå·çœç çŠæ ªåŒäŒç€Ÿ | é£ç¶é³é çšãã³ã°ããºã« |
| US8148141B2 (en) | 2001-05-07 | 2012-04-03 | Hipep Laboratories | Peptide-immobilized substrate and method for measuring target protein |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3864481A (en) * | 1972-12-14 | 1975-02-04 | St Lukes Hospital | Anti disease producing synthetic material for the prevention suppression and diagnosis of multiple sclerosis and method of treatment therefor |
| US4002602A (en) * | 1974-03-11 | 1977-01-11 | Gideon Goldstein | Ubiquitous immunopoietic polypeptide (UBIP) and methods |
| US4113858A (en) * | 1975-01-20 | 1978-09-12 | St. Luke's Hospital | Novel compounds, compositions and methods of their use |
-
1978
- 1978-01-27 SE SE7801031A patent/SE446866B/sv not_active IP Right Cessation
- 1978-02-03 DE DE2804567A patent/DE2804567C2/de not_active Expired
- 1978-02-08 CA CA296,484A patent/CA1105923A/en not_active Expired
- 1978-02-17 FR FR7804598A patent/FR2408581A1/fr active Granted
- 1978-02-20 BE BE185307A patent/BE864122A/xx not_active IP Right Cessation
- 1978-02-22 JP JP1956878A patent/JPS5476522A/ja active Granted
- 1978-02-24 CH CH206378A patent/CH640217A5/de not_active IP Right Cessation
-
1985
- 1985-05-22 JP JP60111321A patent/JPS6150999A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0137400B2 (ja) | 1989-08-07 |
| DE2804567C2 (de) | 1986-01-16 |
| CH640217A5 (en) | 1983-12-30 |
| SE7801031L (sv) | 1979-05-16 |
| FR2408581B1 (ja) | 1983-07-22 |
| SE446866B (sv) | 1986-10-13 |
| JPS5476522A (en) | 1979-06-19 |
| CA1105923A (en) | 1981-07-28 |
| BE864122A (fr) | 1978-08-21 |
| JPS6150999A (ja) | 1986-03-13 |
| FR2408581A1 (fr) | 1979-06-08 |
| DE2804567A1 (de) | 1979-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4190646A (en) | Polypeptide compositions and methods | |
| AU625598B2 (en) | Peptides having t cell helper activity | |
| US4002740A (en) | Tridecapeptide compositions and methods | |
| JPH07165791A (ja) | é µçŽ æµææ§å ç«å€èª¿ãããã | |
| FI67692C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara tripeptider | |
| JPS61218598A (ja) | ãâãœãã€ãšãã³ | |
| US4215111A (en) | Peptides having ubiquitin-like activity | |
| US4190647A (en) | Polypeptides and methods | |
| JPS6149320B2 (ja) | ||
| JPS6118560B2 (ja) | ||
| CA1120031A (en) | Tetrapeptides and methods | |
| US4258151A (en) | Pentapeptide modified resin | |
| US4258152A (en) | Pentapeptide modified resin | |
| HU205143B (en) | Process for producing peptides having t cell suppressor activity and pharmaceutical compositions comprising same | |
| EP0723454A1 (en) | Novel tripeptides useful in immune and cns therapy | |
| US4232008A (en) | Tetrapeptides and methods | |
| GB1565032A (en) | Polypeptide compositions and methods for their manufacture | |
| GB1585736A (en) | Polypeptides and methods for their production |